[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 349
1. Yoshida K, Kinoshita H, Taniguti H, Chizaki R, Nishida T, Hiura Y, Ooguti N, Kawa G, Muguruma K, Matsuda T, Sakaida N, Uemura Y: [Bellini duct carcinoma of the kidney: a case report]. Hinyokika Kiyo; 2007 Feb;53(2):121-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bellini duct carcinoma of the kidney: a case report].
  • We report a case of Bellini duct carcinoma.
  • A 65-year-old man visited our hospital because of an asymptomatic right renal mass directed by ultrasonography and computed tomography in an other hospital.
  • Under the preoperative diagnosis of an atypical right renal tumor, laparoscopic right radical nephrectomy was performed.
  • The histopathological diagnosis was low-grade Bellini duct carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Kidney Tubules, Collecting / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352163.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Okuda H, Tei N, Shimizu K, Imazu T, Yoshimura K, Kiyohara H, Nakamura Y, Fujimura H: [Case report: collecting (Bellini) duct carcinoma during the follow-up for bladder cancer]. Hinyokika Kiyo; 2008 Oct;54(10):665-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case report: collecting (Bellini) duct carcinoma during the follow-up for bladder cancer].
  • A 78-year-old man had undergone transurethral resection of bladder tumor (TUR-Bt) 6 times since he was diagnosed as having bladder cancer.
  • Past histology was urothelial carcinoma, pTa, G1-G2.
  • During the follow-up, recurrent bladder cancer was found.
  • Enhanced computed tomography and drip infusion pyelography revealed pelvic cancer with tumor embolus in the inferior vena cava.
  • The histopathological diagnosis was urothelial carcinoma of the bladder and Bellini duct carcinoma of the kidney, but in immunohistostaining surgical specimen of both bladder and kidney showed some similarities.
  • Several reports indicate an association between Bellini and urothelial carcinoma.
  • We describe the case of the Bellini duct carcinoma of the kidney during the follow-up for bladder cancer with possibility of the association between Bellini and urothelial carcinoma.
  • [MeSH-major] Kidney Neoplasms / pathology. Neoplasms, Second Primary / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoma, Renal Cell. Humans. Male. Neoplasm Recurrence, Local


3. Hsiao HL, Yeh HC, Chang TH, Ke HL, Lin HC, Wu WJ, Huang CH, Lee YC: Renal collecting duct carcinoma and concomitant bladder urothelial carcinoma: a case report. Kaohsiung J Med Sci; 2008 Mar;24(3):157-62
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal collecting duct carcinoma and concomitant bladder urothelial carcinoma: a case report.
  • The simultaneous occurrence of renal collecting duct (Bellini duct) carcinoma and bladder urothelial carcinoma is very rare.
  • A 68-year-old female patient with bladder urothelial carcinoma first received transurethral resection of the tumor.
  • Left side nephrouretectomy and transurethral resection of the intramural ureter were performed 8 months later under the diagnosis of concomitant renal pelvic urothelial carcinoma.
  • However, the final pathologic examination revealed collecting duct carcinoma.
  • Here, we report a rare case of combined renal collecting duct carcinoma and bladder urothelial carcinoma confirmed by pathologic examination and immunohistochemical staining.
  • [MeSH-major] Kidney Neoplasms / pathology. Kidney Tubules, Collecting / pathology. Neoplasms, Multiple Primary / pathology. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Collecting Duct Carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18364277.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


Advertisement
4. Sakura M, Masuda H, Saito K, Koga F, Kawakami S, Kihara K: Collecting duct carcinoma with acquired cystic disease of the kidney in a long-term hemodialysis patient. Int J Urol; 2008 Jan;15(1):93-5
MedlinePlus Health Information. consumer health - Kidney Cysts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collecting duct carcinoma with acquired cystic disease of the kidney in a long-term hemodialysis patient.
  • We report a very rare case of collecting or Bellini duct carcinoma (CDC) found in a 60-year-old male who had received hemodialysis therapy for 21 years.
  • Screening with ultrasonography revealed a solid tumor originating from the cyst wall in the right kidney with acquired cystic disease of the kidney.
  • Subsequent computed tomography (CT) and angiography could not detect another renal tumor.
  • The tumor detected preoperatively was composed of papillary renal cell tumor (RCC) and multiple clear cell carcinoma, pathologically.
  • The histological diagnosis was multiple clear cell carcinomas.
  • [MeSH-major] Carcinoma, Renal Cell / etiology. Kidney Diseases, Cystic / etiology. Kidney Neoplasms / etiology. Renal Dialysis / adverse effects
  • [MeSH-minor] Fatal Outcome. Glomerulonephritis / therapy. Humans. Kidney Failure, Chronic / therapy. Male. Middle Aged. Nephrectomy


5. Fakhrai N, Haitel A, Balassy C, Zielinski CC, Schmidinger M: Major response and clinical benefit following third-line treatment for Bellini duct carcinoma. Wien Klin Wochenschr; 2005 Jan;117(1-2):63-5
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Major response and clinical benefit following third-line treatment for Bellini duct carcinoma.
  • Bellini duct carcinoma accounts for 1-3% of all renal carcinomas and is characterized by an aggressive course and extremely poor prognosis.
  • Conventional treatment for renal-cell carcinoma seems to be ineffective.
  • Since the histology of Bellini duct carcinoma is similar to urothelial carcinoma, chemotherapy for urothelial cancer might be more promising than conventional treatment.
  • We present a patient with renal carcinoma of the left kidney who underwent laparoscopic extrafascial nephrectomy and adrenalectomy.
  • Histopathologic work-up showed Bellini duct carcinoma (pT3a, NX, G3, R0 and M0).
  • Six courses of chemotherapy with cisplatin and gemcitabine were given, a treatment reported to be highly active in urothelial cancer.
  • The combination of cisplatin and gemcitabine was highly active in this patient with metastatic Bellini duct carcinoma, even given as third-line treatment.
  • Histopathologic characteristics should be a major criterion for treatment strategy in renal carcinoma, particularly in Bellini duct carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / secondary. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Kidney Neoplasms / drug therapy. Palliative Care / methods

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986594.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Interleukin-2; 0W860991D6 / Deoxycytidine; 4Z8R6ORS6L / Thalidomide; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Phillips JM, Haskins K, Cooke A: MAdCAM-1 is needed for diabetes development mediated by the T cell clone, BDC-2.5. Immunology; 2005 Dec;116(4):525-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MAdCAM-1 is needed for diabetes development mediated by the T cell clone, BDC-2.5.
  • The NOD-derived islet-reactive CD4(+) T cell clone, BDC-2.5, is able to transfer diabetes to neonatal non-obese diabetic (NOD) mice but is unable to transfer disease to either adult NOD or NOD scid recipients.
  • Transfer of diabetes to adult recipients by BDC-2.5 is only accomplished by cotransfer of CD8(+) T cells from a diabetic donor.

  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diabetes. 1994 Feb;43(2):197-203 [8288043.001]
  • [Cites] J Clin Invest. 1993 Nov;92(5):2509-15 [7693764.001]
  • [Cites] J Immunol. 1994 Jun 15;152(12):5969-78 [8207221.001]
  • [Cites] Adv Exp Med Biol. 1994;355:137-42 [7709812.001]
  • [Cites] Diabetes. 1996 Mar;45(3):328-36 [8593938.001]
  • [Cites] Eur J Immunol. 1996 Aug;26(8):1762-9 [8765018.001]
  • [Cites] Diabetes. 1996 Sep;45(9):1173-80 [8772718.001]
  • [Cites] Diabetes. 1997 Oct;46(10):1542-7 [9313747.001]
  • [Cites] Curr Top Microbiol Immunol. 1998;231:65-83 [9479861.001]
  • [Cites] J Immunol. 1998 Jun 15;160(12):6018-25 [9637517.001]
  • [Cites] Science. 1998 Nov 13;282(5392):1338-41 [9812902.001]
  • [Cites] J Immunol. 2000 Aug 15;165(4):1949-55 [10925277.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2495-504 [11160310.001]
  • [Cites] Immunity. 2003 Jan;18(1):131-40 [12530982.001]
  • [Cites] J Exp Med. 1987 Oct 1;166(4):823-32 [3309126.001]
  • [Cites] J Immunol. 1988 Jan 1;140(1):52-8 [3275717.001]
  • [Cites] Diabetes. 1988 Oct;37(10):1444-8 [2458291.001]
  • [Cites] Eur J Immunol. 1989 Oct;19(10):1947-51 [2684673.001]
  • [Cites] Biochem Soc Trans. 1991 Feb;19(1):187-91 [1903736.001]
  • [Cites] J Immunol. 1994 May 1;152(9):4597-603 [7512601.001]
  • (PMID = 16313366.001).
  • [ISSN] 0019-2805
  • [Journal-full-title] Immunology
  • [ISO-abbreviation] Immunology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK050561; United States / NIDDK NIH HHS / DK / R56 DK050561; United States / NIDDK NIH HHS / DK / DK50561; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Madcam1 protein, mouse
  • [Other-IDs] NLM/ PMC1802433
  •  go-up   go-down


7. Marx K, Bauer J, Guillou L, Delaloye AB, Prior J: Bellini duct carcinoma: visualization on F-18 FDG PET/CT. Clin Nucl Med; 2009 Aug;34(8):541-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bellini duct carcinoma: visualization on F-18 FDG PET/CT.
  • [MeSH-major] Carcinoma, Renal Cell / radiography. Carcinoma, Renal Cell / radionuclide imaging. Fluorodeoxyglucose F18

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617742.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


8. Binetti R, Ceccarelli F, Costamagna FM, D'Angiolini A, Fabri A, Ferri M, Riva G, Roazzi P, Trucchi D, Marcello I: The ISS Carcinogens Data Bank (BDC). Ann Ist Super Sanita; 2008;44(1):31-42
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ISS Carcinogens Data Bank (BDC).
  • The Data Bank on Carcinogens (Banca Dati Cancerogeni, BDC) is a factual data bank, available on the Istituto Superiore di Sanità website, aimed at supporting the risk management decision making of central and local administrators.
  • BDC intends to provide an easy tool for experts, researchers and risk managers dealing with carcinogenic agents.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469374.001).
  • [ISSN] 0021-2571
  • [Journal-full-title] Annali dell'Istituto superiore di sanità
  • [ISO-abbreviation] Ann. Ist. Super. Sanita
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Carcinogens, Environmental
  • [Number-of-references] 40
  •  go-up   go-down


9. Maestroni U, Ferretti S, Dinale F, Froio E, Pilato FP, Ciuffreda M, Mellissari M, Cortellini P: A renal cancer with intermediate characteristics between collecting (Bellini) duct carcinoma and urothelial carcinoma: case report and review of the literature. Tumori; 2006 Nov-Dec;92(6):545-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A renal cancer with intermediate characteristics between collecting (Bellini) duct carcinoma and urothelial carcinoma: case report and review of the literature.
  • Collecting duct carcinoma of the kidney is a rare and aggressive neoplasm of the distal collecting tube, often metastatic at the time of the diagnosis, for which there is no established therapy.
  • We herein describe the case of a 65-year-old man with a renal cancer with a particular immunohistochemical pattern and pathologic aspect.
  • The lesion was diagnosed as a tumor borderline between a urothelial carcinoma with intraductal spreading and a collecting duct carcinoma with calyceal and pelvic spreading.
  • The patient is disease-free 11 months after diagnosis, after radical surgery with adjuvant chemotherapy (carboplatin and gemcitabine) and radiotherapy of a local recurrence.
  • Owing to the common embryologic origin of collecting duct and transitional urothelial cells, several authors have reported an association between collecting duct carcinoma and urothelial cancer.
  • The literature is reviewed to evaluate drugs active against urothelial cancer (like ifosfamide, paclitaxel, carboplatin and gemcitabine).
  • This field should be investigated in the future, in the framework of a neoadjuvant or adjuvant chemotherapy able to support radical surgery for local and advanced collecting duct carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Carcinoma, Transitional Cell / pathology. Kidney Neoplasms / pathology. Urothelium / pathology

  • Genetic Alliance. consumer health - Collecting Duct Carcinoma.
  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17260499.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 21
  •  go-up   go-down


10. Orsola A, Trias I, Raventós CX, Español I, Cecchini L, Orsola I: Renal collecting (Bellini) duct carcinoma displays similar characteristics to upper tract urothelial cell carcinoma. Urology; 2005 Jan;65(1):49-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal collecting (Bellini) duct carcinoma displays similar characteristics to upper tract urothelial cell carcinoma.
  • OBJECTIVES: To describe 3 cases of tumors located in the kidney that may relate collecting (Bellini) duct carcinoma (CDC) to urothelial cell carcinoma (UC).
  • CDC is a subtype of renal cell carcinoma associated with a highly aggressive course, poor prognosis, and limited response to immunotherapy, behaving similarly to UC.
  • METHODS: We present 2 cases of CDC and 1 case of UC of the renal papilla.
  • The urothelial carcinoma from the kidney papilla (case 3) presented carcinoma in situ of the adjacent urothelium and displayed mixed characteristics with CDC, namely location, positive staining for Ulex europaeus and pyelonephritic changes. p53 staining showed marked positivity in the tumor of patient 2.
  • CONCLUSIONS: The results of this study suggest that the broad category of renal cell carcinoma includes a spectrum of lesions.
  • In this range of diseases, CDC might be distinct from conventional renal cell carcinoma but share biologic features with UC, with the consequent implications for management.
  • This association between CDC and UC may reflect the common embryologic origin of collecting duct and urothelial cells, since they derive from progressive branching of the mesonephric (wolffian) duct.
  • Furthermore, the differential cytogenetic expression profiles suggest that the molecular events underlying the development of distal nephron and proximal tubule renal cancers are distinct.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Medulla / pathology. Kidney Neoplasms / pathology. Kidney Tubules, Collecting / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Carcinoma, Transitional Cell / pathology. Humans. Intermediate Filament Proteins / analysis. Keratin-20. Kidney Tubules, Proximal / embryology. Male. Mesonephros. Neoplasm Invasiveness. Neoplasm Proteins / analysis. Neoplasms, Multiple Primary. Nephrons / embryology. Prognosis. Pyelonephritis / complications. Receptors, Cell Surface / analysis. Retrospective Studies. Tumor Suppressor Protein p53 / analysis. Urinary Bladder Neoplasms / pathology. Vimentin / analysis

  • Genetic Alliance. consumer health - Collecting Duct Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667862.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / Keratin-20; 0 / Neoplasm Proteins; 0 / Receptors, Cell Surface; 0 / Tumor Suppressor Protein p53; 0 / Ulex europaeus lectin receptor; 0 / Vimentin
  • [Number-of-references] 24
  •  go-up   go-down


11. Zalatnai A: [Diagnostic difficulties in kidney cancer filling up the retroperitoneal space]. Orv Hetil; 2005 Apr 10;146(15):701-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic difficulties in kidney cancer filling up the retroperitoneal space].
  • An autopsy case of a huge, rapidly progressive Bellini duct carcinoma is presented.
  • The author discusses the pitfalls of diagnosis from clinicopathological point of view.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Kidney Tubules, Collecting / pathology. Retroperitoneal Neoplasms / diagnosis
  • [MeSH-minor] Aged. Autopsy. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15895794.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


12. Amin MB, MacLennan GT, Gupta R, Grignon D, Paraf F, Vieillefond A, Paner GP, Stovsky M, Young AN, Srigley JR, Cheville JC: Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma. Am J Surg Pathol; 2009 Mar;33(3):384-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma.
  • A distinctive tumor described under the terms Bellini duct carcinoma and low-grade collecting duct carcinoma has been referred to by us and others as tubulocystic carcinoma.
  • This renal cell carcinoma subtype is not recognized in the World Health Organization 2004 classification.
  • Herein, we present a detailed study of 31 cases to further characterize this rare subtype of renal cell carcinoma.
  • Immunohistochemistry and ultrastructural examination showed features of proximal convoluted tubules (Pax 2 immunoreactivity and short microvilli with brush border organization) and distal nephron (kidney-specific cadherin immunoreactivity and cytoplasmic interdigitation).
  • Gene expression profiling showed that tubulocystic carcinoma displayed a unique molecular signature.
  • In light of the distinctive clinicopathologic features and a low but definite metastatic potential, this unique subtype of renal cell carcinoma deserves formal recognition in the contemporary classification of renal neoplasms.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011562.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Carrión López P, Giménez Bachs JM, Donate Moreno MJ, Pastor Navarro H, Cañamares Pabolaza L, Segura Martín M, Atienzar Tobarra M, Salinas Sánchez A, Virsedo Rodríguez JA: [Bellini duct carcinoma: report of two cases]. Arch Esp Urol; 2008 Apr;61(3):424-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bellini duct carcinoma: report of two cases].
  • [Transliterated title] Carcinoma de los ductos de Bellini: aportación de dos nuevos casos.
  • OBJECTIVE: We report two cases of collecting duct carcinoma that were diagnosed in our hospital in a six-month period.
  • METHODS/RESULTS: The first case was a 75years-old woman showing in CT scan a mass in the left kidney which infiltrated perinephric fat.
  • The second case was a 72-years-old that showed in a CT scan a right renal pelvis lesion, involving inferior vena cava and renal vein.
  • After surgical resection by radical nephrectomy in both cases, we confirmed the histological diagnosis of collecting duct carcinoma.
  • CONCLUSIONS: Collecting duct carcinoma is a rare variant of renal cell carcinoma which originates from the epithelium of the collecting tubule.
  • It is characterized by both its aggressiveness and peculiar histological and immunohistochemical diagnosis, that separates it from the rest of renal tumors.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Kidney Tubules, Collecting / pathology
  • [MeSH-minor] Aged. Fatal Outcome. Female. Humans. Male. Renal Veins / pathology. Vena Cava, Inferior / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18581680.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


14. Yang XP, Jones RA, Rivers JH, Lai RP: Syntheses, structures and luminescent properties of new lanthanide-based coordination polymers based on 1,4-benzenedicarboxylate (bdc). Dalton Trans; 2007 Sep 21;(35):3936-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Syntheses, structures and luminescent properties of new lanthanide-based coordination polymers based on 1,4-benzenedicarboxylate (bdc).
  • Reaction of 1,4-benzenedicarboxylic acid (1,4-H2BDC) with EuCl(3).6H2O in MeOH in the presence of Et3N and MeCN gives a mixture of the 3-D metal-organic-framework (MOF) materials [Eu2(1,4-BDC)3(MeOH)4].8MeOH (1) and 2-D [Eu(1,4-BDC)(MeOH)4].Cl.MeOH.0.25H2O (2).
  • Reaction of 1,4-H2BDC with Ln(NO3)(3).6H2O under similar conditions gave [Ln(BDC)NO3(MeOH)2].MeCN.H2O (Ln = Eu (5) and Gd (6)), which have 2-D framework structures.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17893791.001).
  • [ISSN] 1477-9234
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Anokhina EV, Vougo-Zanda M, Wang X, Jacobson AJ: In(OH)BDC.0.75BDCH2 (BDC = Benzenedicarboxylate), a hybrid inorganic-organic vernier structure. J Am Chem Soc; 2005 Nov 2;127(43):15000-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In(OH)BDC.0.75BDCH2 (BDC = Benzenedicarboxylate), a hybrid inorganic-organic vernier structure.
  • The compound In(OH)BDC.0.75BDCH2 (BDC = benzenedicarboxylate), 1, has been synthesized and characterized by single-crystal X-ray diffraction.
  • The structure comprises two distinct sublattices formed by a covalently linked In(OH)BDC lattice and ordered chains of hydrogen-bonded H2BDC molecules and can be described as a hybrid inorganic coordination polymer-organic vernier structure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16248619.001).
  • [ISSN] 0002-7863
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Meilikhov M, Yusenko K, Fischer RA: The adsorbate structure of ferrocene inside [Al(OH)(bdc)]x (MIL-53): a powder X-ray diffraction study. Dalton Trans; 2009 Jan 28;(4):600-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The adsorbate structure of ferrocene inside [Al(OH)(bdc)]x (MIL-53): a powder X-ray diffraction study.
  • Ferrocene is strongly adsorbed by the highly porous metal-organic framework compound [Al(OH)(bdc)l], (MIL-53; bdc = 1,4-benzenedicarboxylate).
  • The structure of the crystalline phase {[Fe(eta5-C5H5)2][Al(OH)(bdc)]2}x, was determined by X-ray powder diffraction and Rietveld methods.
  • The ferrocene molecules are arranged in a 1D chain-like fashion and their cyclopentadienyl rings are oriented almost parallel to the O3Al faces of the {AlO6}) octahedra without pi-stacking to the bdc.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19378551.001).
  • [ISSN] 1477-9226
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Kim H, Samsonenko DG, Das S, Kim GH, Lee HS, Dybtsev DN, Berdonosova EA, Kim K: Methane sorption and structural characterization of the sorption sites in Zn2(bdc)2(dabco) by single crystal X-ray crystallography. Chem Asian J; 2009 Jun 2;4(6):886-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methane sorption and structural characterization of the sorption sites in Zn2(bdc)2(dabco) by single crystal X-ray crystallography.
  • Sorption isotherms of methane in Zn(2)(bdc)(2)(dabco) are measured up to a pressure of 35 bar in the temperature range between 198-296 K.
  • The enthalpy of methane adsorption for Zn(2)(bdc)(2)(dabco) estimated by the virial equation is 13.6 kJ mol(-1) at zero coverage.
  • X-ray structure analysis of methane-adsorbed Zn(2)(bdc)(2)(dabco) by synchrotron radiation at 90 K revealed that methane molecules occupy three independent sorption sites (A, B, and C) with a stoichiometry of Zn(2)(bdc)(2)(dabco) x 6.69 CH(4), which is consistent with the results of the gas sorption measurements at 198 K.
  • In a cavity, eight symmetry-related methane sorption sites A are located near the {Zn(2)(CO(2))(4)} paddle-wheel units, while four symmetry-related methane sorption sites B are near the center of the small windows along the a and b axes.
  • Methane molecules occupying sites A are not only in van der Waals contact with the paddle-wheel units, but also interact with the phenyl rings of bdc ligands through partial pi-HC interactions.
  • Methane molecules in B sites interact with the side of the phenyl rings through van der Waals interaction.
  • The site C, located at the center of the cavity, is a secondary sorption site; methane molecules occupying sites C are in van der Waals contact with those in sites A and B.


18. Schröder F, Esken D, Cokoja M, van den Berg MW, Lebedev OI, Van Tendeloo G, Walaszek B, Buntkowsky G, Limbach HH, Chaudret B, Fischer RA: Ruthenium nanoparticles inside porous [Zn4O(bdc)3] by hydrogenolysis of adsorbed [Ru(cod)(cot)]: a solid-state reference system for surfactant-stabilized ruthenium colloids. J Am Chem Soc; 2008 May 14;130(19):6119-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ruthenium nanoparticles inside porous [Zn4O(bdc)3] by hydrogenolysis of adsorbed [Ru(cod)(cot)]: a solid-state reference system for surfactant-stabilized ruthenium colloids.
  • The gas-phase loading of [Zn4O(bdc)3] (MOF-5; bdc = 1,4-benzenedicarboxylate) with the volatile compound [Ru(cod)(cot)] (cod = 1,5-cyclooctadiene, cot = 1,3,5-cyclooctatriene) was followed by solid-state (13)C magic angle spinning (MAS) NMR spectroscopy.
  • Instead, formation of a ruthenium-cyclooctadiene complex with the arene moiety of the bdc linkers of the framework takes place, as revealed by (13)C MAS NMR, PXRD, and TEM.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18402452.001).
  • [ISSN] 1520-5126
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Schröck K, Schröder F, Heyden M, Fischer RA, Havenith M: Characterization of interfacial water in MOF-5 (Zn4(O)(BDC)3)--a combined spectroscopic and theoretical study. Phys Chem Chem Phys; 2008 Aug 28;10(32):4732-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of interfacial water in MOF-5 (Zn4(O)(BDC)3)--a combined spectroscopic and theoretical study.
  • In this article we report the detection and characterization of adsorbed interfacial water within the cages of the metal-organic framework MOF-5 (Zn(4)O(BDC)(3)) by terahertz time-domain spectroscopy (THz TDS) in the frequency range from 5 to 46 cm(-1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688515.001).
  • [ISSN] 1463-9076
  • [Journal-full-title] Physical chemistry chemical physics : PCCP
  • [ISO-abbreviation] Phys Chem Chem Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Larsen RW: How fast do metal organic polyhedra form in solution? Kinetics of [Cu2(5-OH-bdc)2L2]12 formation in methanol. J Am Chem Soc; 2008 Aug 27;130(34):11246-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How fast do metal organic polyhedra form in solution? Kinetics of [Cu2(5-OH-bdc)2L2]12 formation in methanol.
  • The present study utilizes rapid mixing techniques together with fast optical spectroscopy to probe the assembly of [Cu2(5-OH-bdc)2L2]12 formation in methanol.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18671348.001).
  • [ISSN] 1520-5126
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Go YB, Wang X, Anokhina EV, Jacobson AJ: Influence of the reaction temperature and ph on the coordination modes of the 1,4-benzenedicarboxylate (BDC) ligand: a case study of the Ni(II)(BDC)/2,2'-bipyridine system. Inorg Chem; 2005 Nov 14;44(23):8265-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of the reaction temperature and ph on the coordination modes of the 1,4-benzenedicarboxylate (BDC) ligand: a case study of the Ni(II)(BDC)/2,2'-bipyridine system.
  • Three new Ni(BDC)/2,2'-bipy compounds, Ni2(BDC)(HBDC)2(2,2'-bipy)2 (2), Ni3(BDC)3(2,2'-bipy)2 (3), and Ni(BDC)(2,2-bipy)2.2H2O (5), in addition to the previously reported Ni(BDC)(2,2'-bipy).0.75H2BDC (1) and Ni(BDC)(2,2'-bipy)(H2O) (4) [BDC = 1,4-benzenedicarboxylate; 2,2'-bipy = 2,2'-bipyridine], have been synthesized by hydrothermal reactions.
  • At a slightly higher pH, a dimeric molecular compound 2 is formed with a lower number of protonated carboxylate groups per nickel atom and per BDC ligand.
  • Bis-monodentate and bischelating BDC ligands alternate along the chain to give a crankshaft rather than a regular zigzag arrangement.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270964.001).
  • [ISSN] 0020-1669
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Gurrera A, Amico P, Di Cataldo A, Vasquez E, Magro G: [Carcinoma of the Bellini collecting duct in paediatric patients: a case report and review of the literature]. Pathologica; 2007 Oct;99(5):301-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinoma of the Bellini collecting duct in paediatric patients: a case report and review of the literature].
  • [Transliterated title] Carcinoma dei dotti collettori di Bellini in età pediatrica: descrizione di un caso e revisione della letteratura.
  • Collecting duct carcinoma is an uncommon variant of renal cell carcinoma that usually occurs at an earlier age compared to conventional renal cell carcinoma.
  • Renal cell carcinoma rarely occurs in paediatric patients, and is almost always in association with specific genetic alterations; the most common histotypes are the clear cell and chromophobe cell variants.
  • Collecting duct carcinoma is rare, and only 8 cases have been reported in the literature.
  • The authors describe the clinico-pathological features of a fatal collecting duct carcinoma in an 11-year-old boy.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Kidney Tubules, Collecting / pathology

  • Genetic Alliance. consumer health - Collecting Duct Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18354951.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Interleukin-2
  • [Number-of-references] 23
  •  go-up   go-down


23. Staehler M, Haseke N, Schöppler G, Stadler T, Karl A, Siebels M, Ihrler S, Stief CG: Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase-inhibition with sunitinib. Eur J Med Res; 2008 Nov 24;13(11):531-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase-inhibition with sunitinib.
  • INTRODUCTION: Carcinoma of the collecting ducts of Bellini of the kidney (CDC) is very rare but among the most aggressive urological entities.
  • 8 weeks later the patients died with a survival of 8 months from initial diagnosis.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Renal Cell / drug therapy. Indoles / administration & dosage. Kidney Neoplasms / drug therapy. Pyrroles / administration & dosage
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Kidney Tubules, Collecting / pathology. Male. Middle Aged. Protein-Tyrosine Kinases / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19073390.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 2.7.10.1 / Protein-Tyrosine Kinases; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


24. Ohsaki H, Hirakawa E, Kushida Y, Kadota K, Ishikawa M, Haba R: Cytological features of carcinoma of the collecting ducts of Bellini in voided urine cytology. Diagn Cytopathol; 2009 Sep;37(9):676-9
MedlinePlus Health Information. consumer health - Urine and Urination.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological features of carcinoma of the collecting ducts of Bellini in voided urine cytology.
  • Carcinoma of the collecting ducts of Bellini (CCDB) is a rare histological type of renal cell carcinoma.
  • There were various types of cancer cells, including round to oval, spindle, and tadpole-like cells.
  • CCDB of the kidney is a rare cytodiagnostic challenge in voided urine cytology alone.
  • When the cytological diagnosis is considered, it is necessary to perform immunocytochemistry and correlate the clinical history and imaging studies.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / urine. Kidney Neoplasms / pathology. Kidney Neoplasms / urine. Urine / cytology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Wiley-Liss, Inc.
  • (PMID = 19373917.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Kobayashi N, Suzuki K, Shibuya H, Sato T, Aoki I, Nagashima Y: Renal collecting duct carcinoma in a dog. Vet Pathol; 2008 Jul;45(4):489-94
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal collecting duct carcinoma in a dog.
  • Autopsy revealed an invasive grayish-white mass in the right kidney and multiple nodules in the lungs, thoracic wall, and spleen.
  • Histologically, the renal mass and the other nodules were mainly composed of papillotubular structures lined by oval-to-polygonal pleomorphic cells.
  • Because of its histological, histochemical, and immunohistochemical similarities with human collecting duct carcinoma (CDC), a diagnosis of renal collecting duct carcinoma with pulmonary, thoracic, and splenic metastases was established.
  • [MeSH-major] Carcinoma, Renal Cell / veterinary. Dog Diseases / pathology. Kidney Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18587095.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Parker R, Reeves HM, Sudarshan S, Wolff D, Keane T: Abnormal fluorescence in situ hybridization analysis in collecting duct carcinoma. Urology; 2005 Nov;66(5):1110
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for collecting duct carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal fluorescence in situ hybridization analysis in collecting duct carcinoma.
  • Renal collecting duct carcinoma is a rare form of renal cancer known to present in a variety of ways that are often similar to presentations of renal cell carcinoma or transitional cell carcinoma.
  • Little information is available concerning the use of cytology and fluorescence in situ hybridization (FISH) in the diagnosis of collecting duct carcinoma.
  • The available literature contains cases with atypical cytology, but no collecting duct carcinoma cases with abnormal FISH results have been reported.
  • We report a case of renal collecting duct carcinoma presenting with atypical cytology and abnormal FISH results.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. In Situ Hybridization, Fluorescence. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Collecting Duct Carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286148.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 9
  •  go-up   go-down


27. Díaz Pérez JA, Zamora CJ, García Vera JA, Melo Uribe MA, García Ayala E: [Bellini collecting duct renal carcinoma: case report]. Arch Esp Urol; 2008 Jan-Feb;61(1):67-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bellini collecting duct renal carcinoma: case report].
  • [Transliterated title] Carcinoma renal de los túbulos colectores de Belunin: presentación de caso clínico patológico.
  • OBJECTIVE: The collecting duct carcinoma (Bellini's carcinoma) is an unfrequent lesion; its macro and microscopic characteristics can help diagnosis.
  • 65-year-old Colombian woman presenting left-flank and hypochondrio stub-type episodic pain associated with hematuria, nausea and weight loss.
  • RESULTS: The diagnosis was of collecting duct carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Collecting Duct Carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18405031.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 19
  •  go-up   go-down


28. Schlein U: [Modern leadership--what is important. BDC seminar in physician leadership]. Chirurg; 2006 Oct;Suppl:325

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Modern leadership--what is important. BDC seminar in physician leadership].
  • [Transliterated title] Zeitgemässe Leadership--worauf es ankommt. BDC-seminar Arztliche Führung.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17855938.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


29. Ockrim J, Tsiriopoulos I, Rees H, Mendoza N, Christmas TJ: Collecting duct carcinoma of the renal medulla presenting with paraplegia. Int Urol Nephrol; 2005;37(3):465-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collecting duct carcinoma of the renal medulla presenting with paraplegia.
  • We report an interesting case of a patient with collecting duct carcinoma arising from the left kidney who presented with paraplegia secondary to metastases.
  • The diagnosis was based on CT and histology.
  • To our knowledge this is the first case of collecting duct carcinoma to present with paraplegia.
  • [MeSH-major] Carcinoma, Renal Cell / complications. Carcinoma, Renal Cell / diagnosis. Kidney Medulla. Kidney Neoplasms / complications. Kidney Neoplasms / diagnosis. Paraplegia / etiology

  • Genetic Alliance. consumer health - Collecting Duct Carcinoma.
  • Genetic Alliance. consumer health - Paraplegia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1986 Nov;10(11):1131-41 [3542784.001]
  • [Cites] Pathology. 1997 Nov;29(4):354-9 [9423214.001]
  • [Cites] J Urol. 1992 Apr;147(4):1096-8 [1552595.001]
  • [Cites] Br J Urol. 1993 Apr;71(4):388-91 [8499979.001]
  • [Cites] J Urol. 2002 Jan;167(1):71-4 [11743278.001]
  • [Cites] Histopathology. 1991 Feb;18(2):115-22 [1707029.001]
  • [Cites] Hum Pathol. 1990 Apr;21(4):449-56 [2318486.001]
  • (PMID = 16307319.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


30. Rüggeberg JA: [BDC statute changes from the viewpoint of the established surgeon]. Chirurg; 2006 Jul;Suppl:204-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [BDC statute changes from the viewpoint of the established surgeon].
  • [Transliterated title] Die BDC-Satzungsänderungen aus Sicht der Niedergelassenen Chirurgen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17855864.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Staehler M, Schöppler G, Haseke N, Stadler T, Karl A, Siebels M, Ihrler S, Stief CG: Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib. Clin Genitourin Cancer; 2009 Jan;7(1):58-61
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib.
  • BACKGROUND: Carcinoma of the collecting ducts (CDC) of Bellini of the kidney is very rare but is among the most aggressive urologic entities.
  • Eight weeks later, the patients died, with a survival of 8 months from initial diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Kidney Tubules, Collecting / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19213670.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoles; 0 / Pyrroles; 0 / sunitinib; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


32. Ahnfeldt T, Guillou N, Gunzelmann D, Margiolaki I, Loiseau T, Férey G, Senker J, Stock N: [Al4(OH)2(OCH3)4(H2N-bdc)3] x xH(2)O: a 12-connected porous metal-organic framework with an unprecedented aluminum-containing brick. Angew Chem Int Ed Engl; 2009;48(28):5163-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Al4(OH)2(OCH3)4(H2N-bdc)3] x xH(2)O: a 12-connected porous metal-organic framework with an unprecedented aluminum-containing brick.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19504512.001).
  • [ISSN] 1521-3773
  • [Journal-full-title] Angewandte Chemie (International ed. in English)
  • [ISO-abbreviation] Angew. Chem. Int. Ed. Engl.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


33. Liu L, Wang X, Jacobson AJ: AlF.1,4-benzenedicarboxylate: synthesis and absorption properties. Dalton Trans; 2010 Feb 21;39(7):1722-5
Hazardous Substances Data Bank. ALUMINUM FLUORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AlF(bdc), bdc = 1,4-benzenedicarboxylate, a new member of the family of MX(bdc) compounds has been synthesized under solvothermal conditions.
  • It is formed without H(2)bdc in the channels and substantial absorption capacity is observed in its as-synthesized form.
  • AlF(bdc) does not absorb water at ambient temperatures and shows absorption properties similar to VO(bdc).

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20449413.001).
  • [ISSN] 1477-9234
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 1,4-benzenedicarboxylate; 0 / Aluminum Compounds; 0 / Organometallic Compounds; 0 / Phthalic Acids; Q80VPU408O / Fluorides; Z77H3IKW94 / aluminum fluoride
  •  go-up   go-down


34. Smolewska E, Stańczyk J, Brózik H, Biernacka-Zielińska M, Cebula B, Robak T, Smolewski P: Distribution and clinical significance of blood dendritic cells in children with juvenile idiopathic arthritis. Ann Rheum Dis; 2008 Jun;67(6):762-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To analyse distribution and maturation status of blood DC (BDC) in JIA.
  • METHODS: Absolute BDC counts were assessed by the "single platform" method in peripheral blood (PB) of 47 untreated children with JIA and 32 healthy controls.
  • Moreover, BDC were investigated in JIA synovial fluid (SF).
  • When the panel of monoclonal antibodies against BDC antigens (BDCA) was used, three BDC subpopulations were determined: myeloid type 1 (mDC1; BDCA-1+/HLA-DR+/CD19-), myeloid type 2 (mDC2; BDCA-3+/HLA-DR+/CD14-) and plasmacytoid (pDC; BDCA-2+/HLA-DR+/CD123+).
  • RESULTS: A considerable deficiency of all subtypes of BDC was found in the PB of children with JIA.
  • BDC counts in JIA SF were significantly higher than in PB both from children with JIA (p<0.001) and healthy children (p<0.001).
  • SF BDC, especially mDC1 and mDC2 subtypes, had significantly higher expression of maturation markers (CD40, CD80, CD86 or CD83 antigens) than those from PB.
  • A smaller number of PB BDC at diagnosis correlated significantly with poor response to treatment.
  • CONCLUSIONS: A deficiency of BDC in PB is accompanied by enrichment of SF with those cells.
  • Probably, circulating BDC migrate to joints where they undergo maturation and help to mediate and maintain the local immune response.
  • Interestingly, the level of PD BDC deficiency seems to influence the outcome in children with JIA.

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Arthritis, Juvenile.
  • MedlinePlus Health Information. consumer health - Juvenile Arthritis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17965117.001).
  • [ISSN] 1468-2060
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD14; 0 / Antigens, CD19; 0 / Biomarkers; 0 / HLA-DR Antigens; 0 / Interleukin-3 Receptor alpha Subunit
  •  go-up   go-down


35. Kaneoka Y, Yamaguchi A, Isogai M: Hepatopancreatoduodenectomy: its suitability for bile duct cancer versus gallbladder cancer. J Hepatobiliary Pancreat Surg; 2007;14(2):142-8
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatopancreatoduodenectomy: its suitability for bile duct cancer versus gallbladder cancer.
  • BACKGROUND/PURPOSE: We aimed to determine whether bile duct cancer (BDC) or gallbladder cancer (GBC) was a better candidate for hepatopancreatoduodenectomy (HPD).
  • METHODS: Ten patients with BDC and ten with GBC were treated by HPD with major hepatectomy between 1994 and 2004 and compared, in terms of surgical outcome and survival.
  • RESULTS: In the BDC patients, the International Union Against Cancer (UICC) stage was I in three patients; II in four; III in one; and IV in two; of the GBC patients, one was stage II; four were stage III; and five were stage IV.
  • The reasons for choosing HPD for BDC were: superficial spreading, in three patients; intramural wide invasion, in five; and hepatoduodenal ligament (HDL) invasion, in two; and for GBC, extrahepatic bile duct invasion, in seven; and HDL invasion, in three.
  • The morbidity and mortality rates for BDC and GBC were 40% and 60%, and 0% and 30%, respectively.
  • The cumulative 5-year survival rate of the BDC patients was 64%; the 1-year survival rate for the GBC patients was only 20%, and none survived for over 2 years (P < 0.001).
  • Of the patterns of BDC cancer invasion, the superficial-spreading type appeared to have a better prognosis than the others, but the difference was not statistically significant.
  • CONCLUSIONS: HPD is indicated for any type of BDC, but HPD did not show any survival benefits in treating patients with GBC with obstructive jaundice.
  • [MeSH-major] Adenocarcinoma / surgery. Bile Duct Neoplasms / surgery. Cholangiocarcinoma / surgery. Gallbladder Neoplasms / surgery. Hepatectomy / methods. Pancreaticoduodenectomy / methods

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17384904.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


36. Chaushu S, Bongart M, Aksoy A, Ben-Bassat Y, Becker A: Buccal ectopia of maxillary canines with no crowding. Am J Orthod Dentofacial Orthop; 2009 Aug;136(2):218-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Buccally displaced canines (BDC) are usually found in crowded dentitions.
  • Nevertheless, a small but significant number of patients with BDC have no crowding.
  • In this study, we compared BDC dentitions with no crowding (BDC-nc), BDC dentitions with crowding (BDC-c), and uncrowded dentitions with normally erupted canines (C).
  • METHODS: The mesiodistal (MD) widths of maxillary permanent teeth, the prevalence of maxillary lateral incisor anomalies, and the dental age were compared in BDC-nc (n = 30; 17 male, 13 female), BDC-c (n = 41; 21 male, 20 female), and C dentitions (n = 40; 20 male, 20 female).
  • RESULTS: No differences in the MD dimensions of the teeth in the BDC-nc and C subjects were found; teeth in the BDC-c group were slightly larger.
  • Only the lateral incisor was consistently smaller in the BDC-nc group.
  • The prevalence of lateral incisor anomalies was markedly increased in the BDC-nc (28.3%) compared with the BDC-c (7.6%) and the C (8.6%) groups.
  • CONCLUSIONS: These findings suggest that, in addition to a genetically based etiology, buccal displacement in BDC-nc subjects might also be the result of lack of guidance from an adjacent anomalous lateral incisor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Orthod Dentofacial Orthop. 2009 Nov;136(5):623; author reply 623 [19892266.001]
  • (PMID = 19651351.001).
  • [ISSN] 1097-6752
  • [Journal-full-title] American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics
  • [ISO-abbreviation] Am J Orthod Dentofacial Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Jariwala AC, Scott I, Arnold GP, Abboud RJ, Wigderowitz CA: Objective assessment of the alterations in wrist mobility with the fastrak(®) system following dorsal capsulodesis. Hand Surg; 2010;15(3):237-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The treatment for scapholunate dissociation is challenging and its management is varied depending on type, severity and duration of injury, and surgeon's preferred technique.
  • This study aimed to objectively assess the variations in the range and patterns of wrist movements using the Fastrak(®) system in patients having undergone Blatt's dorsal capsulodesis (BDC).
  • Following BDC the mean flexion loss was 23° (range 10°-38°).
  • However, functional tasks revealed that the BDC did not adversely affect the function of the operated wrist.
  • This novel study demonstrates objectively the functional restrictions that patients are likely to experience postoperatively following BDC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21089203.001).
  • [ISSN] 1793-6535
  • [Journal-full-title] Hand surgery : an international journal devoted to hand and upper limb surgery and related research : journal of the Asia-Pacific Federation of Societies for Surgery of the Hand
  • [ISO-abbreviation] Hand Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


38. Assad L, Resetkova E, Oliveira VL, Sun W, Stewart JM, Katz RL, Caraway NP: Cytologic features of renal medullary carcinoma. Cancer; 2005 Feb 25;105(1):28-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic features of renal medullary carcinoma.
  • BACKGROUND: Renal medullary carcinoma is a rare tumor that is most common in young black men with sickle cell disease or trait.
  • Patients often present with advanced disease at the time of diagnosis, and their prognosis is poor, even with aggressive therapy.
  • The clinical and pathologic features of renal medullary carcinoma have been described in several articles, but reports describing the cytologic features are rare.
  • METHODS: In the current report, the authors describe the cytologic features of three cases of renal medullary carcinoma.
  • RESULTS: All three patients presented with hematuria, flank pain, and a renal mass.
  • CONCLUSIONS: Renal medullary carcinoma should be considered in the differential diagnosis of patients who present with hematuria or a renal mass, especially in young black men with sickle cell disease or trait.
  • Cytologically, renal medullary carcinoma cells appear similar to the cells in high-grade carcinoma.
  • Immunohistochemical studies can be helpful in distinguishing renal medullary carcinoma from other poorly differentiated kidney tumors, except for collecting duct carcinoma.
  • The clinical findings are key to diagnosing renal medullary carcinoma.
  • [MeSH-major] Carcinoma, Medullary / pathology. Kidney Neoplasms / pathology. Sickle Cell Trait / complications
  • [MeSH-minor] Adult. Diagnosis, Differential. Hematuria / diagnosis. Humans. Male

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 American Cancer Society
  • (PMID = 15593260.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Nutramon T, Supachart C: Influence of driving cycles on exhaust emissions and fuel consumption of gasoline passenger car in Bangkok. J Environ Sci (China); 2009;21(5):604-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A newly established Bangkok driving cycle (BDC) and the European driving cycle (EDC) which is presently adopted as the legislative cycle for testing automobiles registered in Thailand were used.
  • The newly developed BDC is constructed using the driving characteristic data obtained from the real on-road driving tests along selected traffic routes.
  • Variations of keyed driving parameters of BDC with different driving cycles were discussed.
  • The results showed that the HC and CO emission factors of BDC are almost two and four times greater than those of EDC, respectively.
  • Although the difference in the NOx emission factor is small, the value from BDC is still greater than that of EDC by 10%.
  • Under BDC, the test vehicle consumes fuel about 25% more than it does under EDC.
  • All these differences are mainly attributed to the greater proportion of idle periods and higher fluctuations of vehicle speed in the BDC cycle.
  • This result indicated that the exhausted emissions and fuel consumption of vehicles obtained from tests under the legislative modal-type driving cycle (EDC) are significantly different from those actually produced under real traffic conditions especially during peak periods.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20108661.001).
  • [ISSN] 1001-0742
  • [Journal-full-title] Journal of environmental sciences (China)
  • [ISO-abbreviation] J Environ Sci (China)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Gasoline; 0 / Vehicle Emissions
  •  go-up   go-down


40. Brixner DI, Joish VN, Odera GM, Avey SG, Hanson DM, Cannon HE: Effects of benefit design change across 5 disease states. Am J Manag Care; 2007 Jun;13(6 Pt 2):370-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the effects of benefit design change (BDC) on medication adherence and persistence (including switch in therapy), drug costs, and total healthcare costs.
  • METHODS: Continuously enrolled patients in 2001 and 2002 with allergic rhinitis, asthma, diabetes mellitus, hypertension, or osteoarthritis belonged to employer groups with or without a pharmacy BDC as of January 1, 2002.
  • RESULTS: Compared with the group without BDC, the proportion of patients who discontinued drug therapy was significantly greater in the BDC group among those with allergic rhinitis (67% vs 54%), asthma (66% vs 50%), osteoarthritis (61% vs 36%), and hypertension (39% vs 18%) (P < .05 for all).
  • Medication compliance was not affected by BDC.
  • The year-to-year pharmacy costs per patient in the BDC group decreased $305 for patients with osteoarthritis (P < .001) and $95 for patients with allergic rhinitis (P = .03).
  • There was no significant effect on overall healthcare costs in any disease state during the year following the BDC.
  • CONCLUSION: A pharmacy BDC may result in decreased pharmacy costs, with no effect on overall healthcare costs within 1 year for patients with allergic rhinitis, asthma, hypertension, or osteoarthritis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17567238.001).
  • [ISSN] 1936-2692
  • [Journal-full-title] The American journal of managed care
  • [ISO-abbreviation] Am J Manag Care
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


41. Yoon SK, Nam KJ, Rha SH, Kim JK, Cho KS, Kim B, Kim KH, Kim KA: Collecting duct carcinoma of the kidney: CT and pathologic correlation. Eur J Radiol; 2006 Mar;57(3):453-60
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collecting duct carcinoma of the kidney: CT and pathologic correlation.
  • PURPOSE: We characterized CT findings of collecting duct carcinoma of the kidney and correlated these with the histopathologic findings.
  • MATERIALS AND METHODS: CT scans of 18 patients with pathologically proven collecting duct carcinoma of the kidney were retrospectively reviewed.
  • We analyzed CT findings of collecting duct carcinoma and also correlated CT findings with the histopathologic findings.
  • Seventeen (94%) tumors had a medullary location.
  • In 17 (94%) of the 18 cases, involvement of the renal sinus was present.
  • Infiltrative growth (67%) and preservation of the renal contour (61%) were more common than expansile growth (33%) and exophytic configuration (39%), respectively.
  • CONCLUSION: Medullary location, weak and heterogeneous enhancement, involvement of the renal sinus, infiltrative growth, preserved renal contour, and a cystic component are CT findings frequently seen in patients with collecting duct carcinoma of the kidney.
  • CT findings are nevertheless nonspecific and do not allow collecting duct carcinoma to be easily differentiated from the other subtypes of renal cell carcinoma.
  • However, when CT demonstrates a renal tumor with these findings, collecting duct carcinoma can be considered in the differential diagnosis.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Female. Humans. Kidney Medulla. Lymphatic Diseases / diagnosis. Male. Middle Aged. Neoplasm Metastasis. Renal Veins / pathology. Retrospective Studies

  • Genetic Alliance. consumer health - Collecting Duct Carcinoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266796.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


42. Li ZY, Dai JW, Yue ST: Poly[[(μ-1H-benzimidazole-5,6-dicarboxyl-ato)zinc(II)] monohydrate]. Acta Crystallogr Sect E Struct Rep Online; 2009;65(Pt 7):m775
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The three-dimensional polymeric title compound, {[Zn(C(9)H(4)N(2)O(4))]·H(2)O}(n), contains one crystallographically independent Zn(II) atom, one fully deprotonated 1H-benzimid-azole-5,6-dicarboxyl-ate (bdc) ligand and one uncoordinated water mol-ecule.
  • The Zn(II) atom is four-coordinated by three O atoms and one N atom from the bdc ligands, giving a distorted tetra-hedral coordination geometry.
  • The uncoordinated water mol-ecule is bound to the main structure through a strong bdc-water N-H⋯O hydrogen bond, and two much weaker water-bdc O-H⋯O inter-actions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Crystallogr C. 2007 May;63(Pt 5):m216-9 [17478904.001]
  • [Cites] Acta Crystallogr A. 2008 Jan;64(Pt 1):112-22 [18156677.001]
  • [Cites] Acta Crystallogr Sect E Struct Rep Online. 2008;64(Pt 7):m928 [21202783.001]
  • (PMID = 21582705.001).
  • [ISSN] 1600-5368
  • [Journal-full-title] Acta crystallographica. Section E, Structure reports online
  • [ISO-abbreviation] Acta Crystallogr Sect E Struct Rep Online
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2969483
  •  go-up   go-down


43. Nakamura H, Kuirhara Y, Matsushita K, Sakai A, Yamaguchi T, Nakajima Y: Extrarenal multiorgan metastases of collecting duct carcinoma of the kidney: a case series. J Med Case Rep; 2008;2:304

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrarenal multiorgan metastases of collecting duct carcinoma of the kidney: a case series.
  • INTRODUCTION: Collecting duct carcinoma is a rare type of renal cell carcinoma.
  • CASE PRESENTATION: We present two case reports of multiorgan metastases of collecting duct carcinoma that were autopsy confirmed.
  • Abdominal computed tomography showed enlargement of the right kidney.
  • These lesions were biopsied, resulting in a histological diagnosis of metastatic adenocarcinoma.
  • A renal tumor was considered.
  • Transitional cell carcinoma was suspected, which proved to be misdiagnosed and chemotherapy was given accordingly.
  • Autopsy demonstrated the primary tumor to be collecting duct carcinoma, with metastases to lung, liver, spleen, bone marrow, right adrenal gland, and para-aortic lymph node.
  • Computed tomography revealed a progressively enlarging right renal lesion, multiple liver masses, enlargement of the para-aortic lymph nodes, and multiple osteoblastic and osteoclastic lesions.
  • A renal tumor with multiple metastases was diagnosed.
  • Autopsy revealed a primary tumor of collecting duct carcinoma with metastases to the liver, right adrenal gland, right upper ureter, bone marrow, para-aortic and mediastinal lymph nodes, and bone.
  • CONCLUSION: We present the radiological findings of lung, liver, lymph node, and bone metastases in two patients with collecting duct carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1986 Nov;10(11):1131-41 [3542784.001]
  • [Cites] Hum Pathol. 1990 Apr;21(4):449-56 [2318486.001]
  • [Cites] J Urol. 2003 Apr;169(4):1287-90 [12629344.001]
  • [Cites] AJR Am J Roentgenol. 2001 Mar;176(3):627-33 [11222193.001]
  • [Cites] Histopathology. 1991 Feb;18(2):115-22 [1707029.001]
  • [Cites] J Urol. 2000 Apr;163(4):1090-5; quiz 1295 [10737472.001]
  • [Cites] Eur J Radiol. 2006 Mar;57(3):453-60 [16266796.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):54-67 [9503506.001]
  • [Cites] J Comput Assist Tomogr. 1996 May-Jun;20(3):399-403 [8626899.001]
  • [Cites] Arch Esp Urol. 2000 Sep;53(7):611-6 [11037654.001]
  • (PMID = 18798981.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2556681
  •  go-up   go-down


44. Bulloch K, Miller MM, Gal-Toth J, Milner TA, Gottfried-Blackmore A, Waters EM, Kaunzner UW, Liu K, Lindquist R, Nussenzweig MC, Steinman RM, McEwen BS: CD11c/EYFP transgene illuminates a discrete network of dendritic cells within the embryonic, neonatal, adult, and injured mouse brain. J Comp Neurol; 2008 Jun 10;508(5):687-710
SciCrunch. The Antibody Registry: Reagent: Antibodies .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our anatomic results showed discrete populations of EYFP(+) brain dendritic cells (EYFP(+) bDC) that colocalized with a small fraction of microglia immunoreactive for Mac-1, Iba-1, CD45, and F4/80 but not for NeuN, Dcx, NG2 proteoglycan, or GFAP.
  • EYFP(+) bDC, isolated by fluorescent activated cell sorting (FACS), expressed mRNA for the Itgax (CD11c) gene, whereas FACS anlaysis of EYFP(+) bDC cultures revealed the presence of CD11c protein.
  • Light microscopy studies revealed that EYFP(+) bDC were present in the embryonic CNS when the blood-brain barrier is formed and postnatally when brain cells are amenable to culturing.
  • In adult male mice, EYFP(+) bDC distribution was prominent within regions of the CNS that 1) are subject to structural plasticity and neurogenesis, 2) receive sensory and humoral input from the external environment, and 3) lack a blood-brain barrier.
  • Ultrastructural analysis of EYFP(+) bDC in adult neurogenic niches showed their proximity to developing neurons and a morphology characteristic of immune/microglia cells.
  • Kainic acid-induced seizures revealed that EYFP(+) bDC responded to damage of the hippocampus and displayed morphologies similar to those described for seizure-activated EGFP(+) microglia in the hippocampus of cfms (CSF-1R) EGFP mice.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386786.001).
  • [ISSN] 1096-9861
  • [Journal-full-title] The Journal of comparative neurology
  • [ISO-abbreviation] J. Comp. Neurol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL18974; United States / PHS HHS / / NA16765; United States / NINDS NIH HHS / NS / NS007080; United States / PHS HHS / / PA08259
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD11c; 0 / Bacterial Proteins; 0 / Luminescent Proteins; 0 / yellow fluorescent protein, Bacteria
  •  go-up   go-down


45. Strouse JJ, Spevak M, Mack AK, Arceci RJ, Small D, Loeb DM: Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer; 2005 Apr;44(4):407-11
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant responses to platinum-based chemotherapy in renal medullary carcinoma.
  • Most patients with renal medullary carcinoma (RMC) have advanced disease at presentation and rarely respond to radiation or chemotherapy.
  • [MeSH-major] Carboplatin / therapeutic use. Carcinoma, Renal Cell / drug therapy. Cisplatin / therapeutic use. Deoxycytidine / analogs & derivatives. Kidney Medulla. Kidney Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Blood Cancer. 2006 Aug;47(2):228 [16514612.001]
  • (PMID = 15602719.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 21
  •  go-up   go-down


46. Waldner H, Sobel RA, Price N, Kuchroo VK: The autoimmune diabetes locus Idd9 regulates development of type 1 diabetes by affecting the homing of islet-specific T cells. J Immunol; 2006 May 1;176(9):5455-62
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The autoimmune diabetes locus Idd9 regulates development of type 1 diabetes by affecting the homing of islet-specific T cells.
  • To determine the effect of Idd9 on the function of islet-specific T cells, we established novel BDC-Idd9 mice that harbor BDC2.5 TCR transgenic T cells containing the Idd9 of diabetes-resistant B10 mice.
  • We show that the development and functional responses of islet-specific T cells from BDC-Idd9 mice are not defective compared with those from BDC mice, which contain the Idd9 of diabetes-susceptible NOD mice.
  • Upon transfer, BDC T cells rapidly induced severe insulitis and diabetes in NOD.scid mice, whereas those from BDC-Idd9 mice mediated a milder insulitis and induced diabetes with a significantly delayed onset.
  • BDC and BDC-Idd9 T cells expanded comparably in recipient mice.
  • However, BDC-Idd9 T cells accumulated in splenic periarteriolar lymphatic sheaths, whereas BDC T cells were mainly found in pancreatic lymph nodes and pancreata of recipients, indicating that the transferred T cells differed in their homing.
  • We provide evidence that the migration pattern of transferred BDC and BDC-Idd9 T cells at least partly depends on their differential chemotaxis toward the CCR7 ligand CCL19.
  • Taken together, our data show that the Idd9 locus regulates development of type 1 diabetes by affecting the homing of islet-specific T cells.
  • [MeSH-major] Cell Movement / immunology. Diabetes Mellitus, Type 1 / genetics. Diabetes Mellitus, Type 1 / pathology. Islets of Langerhans / metabolism. Islets of Langerhans / pathology. T-Lymphocytes / metabolism. T-Lymphocytes / pathology

  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16622013.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI 44880
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ccr7 protein, mouse; 0 / Ligands; 0 / Receptors, CCR7; 0 / Receptors, Chemokine
  •  go-up   go-down


47. Xu ZL, Ma XY, Ma S, Wang XY: Poly[bis(mu-benzene-1,4-dicarboxylato)bis[mu-6-(4-pyridyl)-5H-imidazolo[4,5-f][1,10]phenanthroline]dilead(II)]: an interpenetrating alpha-Po net. Acta Crystallogr C; 2010 Sep;66(Pt 9):m245-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The asymmetric unit of the title compound, [Pb(2)(C(8)H(4)O(4))(2)(C(18)H(11)N(5))(2)](n), contains two Pb(II) atoms, two benzene-1,4-dicarboxylate (1,4-bdc) dianions and two 6-(4-pyridyl)-5H-imidazolo[4,5-f][1,10]phenanthroline (L) ligands.
  • Each Pb(II) atom is eight-coordinated by three N atoms from two different L ligands and five carboxylate O atoms from three different 1,4-bdc dianions.
  • The two 1,4-bdc dianions (1,4-bdc(1) and 1,4-bdc(2)) show different coordination modes.
  • Each 1,4-bdc(1) coordinates to two Pb(II) atoms in a chelating bis-bidentate mode.
  • Each carboxylate group of the 1,4-bdc(2) anion connects two Pb(II) atoms in a chelating-bridging tridentate mode to form a dinuclear unit.
  • Neighbouring dinuclear units are connected together by the aromatic backbone of the 1,4-bdc dianions and the L ligands into a three-dimensional six-connected alpha-polonium framework.
  • The most striking feature is that two identical three-dimensional single alpha-polonium nets are interlocked with each other, thus leading directly to the formation of a twofold interpenetrated three-dimensional alpha-polonium architecture.
  • The framework is held together in part by strong N-H...O hydrogen bonds between the imidazole NH groups of the L ligands and the carboxylate O atoms of 1,4-bdc dianions within different alpha-polonium nets.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20814095.001).
  • [ISSN] 1600-5759
  • [Journal-full-title] Acta crystallographica. Section C, Crystal structure communications
  • [ISO-abbreviation] Acta Crystallogr C
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


48. Katsura Y, Kobayashi S, Wada H, Marubashi S, Eguchi H, Takeda Y, Tanemura M, Umeshita K, Wakasa K, Doki Y, Mori M, Nagano H: [A case of curative resected hilar bile duct cancer with hepatic artery and portal vein reconstructions]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2720-2
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of curative resected hilar bile duct cancer with hepatic artery and portal vein reconstructions].
  • The indication for surgical resection due to hilar bile duct cancer (BDC) with vessel reconstructions is still controversial.
  • We report herein a successfully resected case due to hilar BDC with hepatic artery (HA) and portal vein (PV) reconstructions using autograft from a resected liver.
  • A 57-year-old woman was diagnosed as hilar BDC, and computed tomography showed a tumor invaded left and common hepatic duct, right and left HA, and left main branch of PV.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Extrahepatic. Hepatic Artery / surgery. Portal Vein / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224691.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


49. Gottfried-Blackmore A, Kaunzner UW, Idoyaga J, Felger JC, McEwen BS, Bulloch K: Acute in vivo exposure to interferon-gamma enables resident brain dendritic cells to become effective antigen presenting cells. Proc Natl Acad Sci U S A; 2009 Dec 8;106(49):20918-23
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previously, in a CD11c/EYFP transgenic mouse developed to study DC functions, we anatomically mapped and phenotypically characterized a discrete population of EYFP(+) cells within the microglia that we termed brain dendritic cells (bDC).
  • The administration of IFNgamma increased the number of EYFP(+)bDC but did not recruit peripheral DC into the CNS.
  • In addition, IFNgamma-activated EYFP(+)bDC induced antigen-specific naïve CD4 T cells to proliferate and secrete Th1/Th17 cytokines.
  • Activated bDC were also able to stimulate naïve CD8 T cells.
  • Collectively, these data reveal the Th1 cytokine IFNgamma, but not the Th2 cytokine IL4, induces bDC to up-regulate MHC-II and become competent APC.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuroimmunol. 2000 Jul 24;107(2):111-7 [10854644.001]
  • [Cites] J Immunol. 2000 Mar 1;164(5):2759-68 [10679118.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 22;98(11):6295-300 [11371643.001]
  • [Cites] Nat Rev Immunol. 2002 Mar;2(3):151-61 [11913066.001]
  • [Cites] Eur J Neurosci. 2002 Dec;16(11):2113-22 [12473079.001]
  • [Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):31-44 [12952284.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):8981-6 [15184678.001]
  • [Cites] J Neurol Sci. 1987 Aug;80(1):25-37 [3302117.001]
  • [Cites] J Neuroimmunol. 1991 Nov;34(2-3):121-32 [1918319.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):574-8 [1370583.001]
  • [Cites] J Immunol. 1995 Jan 15;154(2):944-53 [7814894.001]
  • [Cites] J Immunol. 1995 May 1;154(9):4309-21 [7722289.001]
  • [Cites] Science. 1995 Jul 28;269(5223):549-52 [7624779.001]
  • [Cites] Microsc Res Tech. 1995 Nov 1;32(4):267-85 [8573777.001]
  • [Cites] Trends Neurosci. 1996 Aug;19(8):331-8 [8843602.001]
  • [Cites] J Immunol. 1998 May 15;160(10):4671-80 [9590212.001]
  • [Cites] J Comp Neurol. 1999 Mar 15;405(3):322-33 [10076928.001]
  • [Cites] J Comp Neurol. 1999 Mar 22;405(4):553-62 [10098945.001]
  • [Cites] Brain Res Brain Res Rev. 1999 Jul;30(1):77-105 [10407127.001]
  • [Cites] Eur J Immunol. 1999 Sep;29(9):2705-14 [10508245.001]
  • [Cites] Nat Immunol. 2004 Dec;5(12):1243-50 [15543150.001]
  • [Cites] Nat Med. 2005 Mar;11(3):328-34 [15735653.001]
  • [Cites] Mol Cell Neurosci. 2005 Jul;29(3):381-93 [15890528.001]
  • [Cites] Trends Neurosci. 2006 Feb;29(2):68-74 [16406093.001]
  • [Cites] J Neurotrauma. 2006 Mar-Apr;23(3-4):360-70 [16629622.001]
  • [Cites] J Immunol. 2000 Feb 15;164(4):1705-12 [10657614.001]
  • [Cites] Nat Rev Immunol. 2009 Jun;9(6):393-407 [19444307.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11784-9 [16864778.001]
  • [Cites] Glia. 2007 Mar;55(4):412-24 [17203473.001]
  • [Cites] Nat Immunol. 2007 Feb;8(2):172-80 [17206145.001]
  • [Cites] Nature. 2007 Sep 27;449(7161):419-26 [17898760.001]
  • [Cites] Cytometry B Clin Cytom. 2007 Nov;72(6):458-64 [17397063.001]
  • [Cites] Glia. 2008 Jan 1;56(1):69-77 [17932942.001]
  • [Cites] Nat Med. 2008 Mar;14(3):337-42 [18278054.001]
  • [Cites] J Comp Neurol. 2008 Jun 10;508(5):687-710 [18386786.001]
  • [Cites] Nat Rev Immunol. 2008 May;8(5):362-71 [18379575.001]
  • [Cites] Trends Immunol. 2008 May;29(5):227-34 [18396103.001]
  • [Cites] J Exp Med. 2008 Oct 27;205(11):2633-42 [18852291.001]
  • [Cites] Nat Immunol. 2009 May;10(5):514-23 [19305396.001]
  • [Cites] Am J Pathol. 2009 May;174(5):1799-807 [19359516.001]
  • [Cites] Glia. 2009 Sep;57(12):1341-50 [19229994.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2717-26 [11160337.001]
  • (PMID = 19906988.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD11c; 0 / Bacterial Proteins; 0 / Ccr7 protein, mouse; 0 / Epitopes; 0 / Histocompatibility Antigens Class II; 0 / Luminescent Proteins; 0 / Receptors, CCR7; 0 / yellow fluorescent protein, Bacteria; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


50. Søreide K, Søreide JA: Bile duct cyst as precursor to biliary tract cancer. Ann Surg Oncol; 2007 Mar;14(3):1200-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bile duct cyst as precursor to biliary tract cancer.
  • BACKGROUND: Bile duct cysts (BDC) are rare, of uncertain origin, and occur most often in young females of Asian descent.
  • Increasingly, BDCs are reported in the Western population, often with coexistent biliary tract cancer.
  • METHODS: The PubMed and Medline literature databases were searched for pertinent publications regarding the clinical association and molecular biological development of cancerogenesis in BDC.
  • RESULTS: Cancer is found in 10-30% of adults with BDC.
  • The cancer-risk is low in childhood (<1% in the first decade), and shows a clear increase with age.
  • Cholangiocarcinoma is the most common malignancy in BDC, and represents a 20- to 30-fold risk compared to the general population.
  • The mean age of malignancy in BDC is 32 years (about two decades earlier than in the general population).
  • Type I and type IV cysts show a higher cancer incidence, even after cyst excision.
  • Pathological findings strongly suggest a hyperplasia-dysplasia-carcinoma sequence in carcinogenesis of pancreatico-biliary maljunction (PBM).
  • Reflux of pancreatic enzymes, amylase, bile stasis, and an increased intraductal concentration of bile acids contribute to proliferative activity of bile acids in BDC.
  • CONCLUSION: Increased molecular knowledge substantiates the clinically related cancer-risk in BDC.
  • Surgery remains the golden standard for treatment, relieves patients from associated complications, and interrupts the cancerous potential in BDC.
  • [MeSH-major] Bile Duct Diseases / pathology. Biliary Tract Neoplasms / diagnosis. Cysts / pathology


51. Shin BS, Kim JJ, Kim J, Hu SK, Kim HJ, Hong SH, Kim HK, Lee HS, Yoo SD: Oral bioavailability and enterohepatic recirculation of otilonium bromide in rats. Arch Pharm Res; 2008 Jan;31(1):117-24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A sensitive LC/MS/MS assay (LLOQ 0.5 ng/mL) was developed for the determination of otilonium and applied to i.v. and oral administration studies in bile duct cannulated (BDC) and non-BDC rats.
  • After i.v. injection to BDC rats (1 mg/ kg as otilonium), average t(1/2), CL, Vz and AUC were 7.9 +/- 1.9 h, 8.7 +/- 3.1 mL/min/kg, 5.7 +/- 1.4 L/kg and 2,088 +/- 676 ng h/mL, respectively, and these values were comparable to those found in non-BDC rats.
  • The percentages of i.v. dose excreted unchanged in bile and urine in BDC rats were 11.6 +/- 3.0 and 3.1 +/- 0.7%, respectively.
  • Upon oral administration to non-BDC rats (20 mg/kg as otilonium), t(1/2), Cmax, Tmax and AUC were 6.4 +/- 1.3 h, 182.8 +/- 44.6 ng/mL, 1.9 +/- 1.6 h and 579 +/- 113 ng h/mL, respectively.
  • A secondary peak was observed in the serum concentration-time profiles in non-BDC rats following both i.v. and oral administration, indicating that otilonium bromide was subject to enterohepatic recirculation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18277617.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Parasympatholytics; 0 / Quaternary Ammonium Compounds; 26095-59-0 / octylonium
  •  go-up   go-down


52. Vari F, Munster DJ, Hsu JL, Rossetti TR, Mahler SM, Gray PP, Turtle CJ, Prue RL, Hart DN: Practical blood dendritic cell vaccination for immunotherapy of multiple myeloma. Br J Haematol; 2008 Nov;143(3):374-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have developed a bio-process to purify CMRF-56 monoclonal antibody (mAb) and a standard operating procedure to immunoselect blood dendritic cells (BDC).
  • Leucopheresed mononuclear cells were cultured overnight, labelled with CMRF-56 mAb and BDC prepared using a clinical scale immunoselection system.
  • The mean BDC yield from healthy donors was 48% (n = 6, purity 28%).
  • This procedure can be performed readily by clinical cell manufacturing units to facilitate BDC vaccination studies.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Dendritic Cells / transplantation. Multiple Myeloma / therapy

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18729856.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Differentiation; 0 / Antigens, Neoplasm; 0 / CMRF-56 antigen; 0 / Cancer Vaccines
  •  go-up   go-down


53. Diao YP, Li K, Huang SS, Shu XH, Liu KX, Deng XM: A novel threefold-interpenetrating primitive cubic network based on a dinuclear Zn2 node. Acta Crystallogr C; 2009 Feb;65(Pt 2):m82-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the mixed-ligand metal-organic polymeric compound poly[[mu(2)-1,4-bis(imidazol-1-yl)benzene](mu(2)-terephthalato)dizinc(II)], [Zn(2)(C(8)H(4)O(4))(2)(C(12)H(10)N(4))](n) or [Zn(2)(bdc)(2)(bib)](n) [H(2)bdc is terephthalic acid and bib is 1,4-bis(imidazol-1-yl)benzene], the asymmetric unit contains one Zn(II) ion, with two half bdc anions and one half bib molecule lying around inversion centers.
  • The Zn(II) ion is in a slightly distorted tetrahedral environment, coordinated by three carboxylate O atoms from three different bdc anions and by one bib N atom.
  • The crystal structure is constructed from the secondary building unit (SBU) [Zn(2)(CO(2))(2)N(2)O(2)], in which the two metal centers are held together by two bdc linkers with bis(syn,syn-bridging bidentate) bonding modes.
  • The SBU is connected by bdc bridges to form a two-dimensional grid-like (4,4)-layer, which is further pillared by the bib ligand.

  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190377.001).
  • [ISSN] 1600-5759
  • [Journal-full-title] Acta crystallographica. Section C, Crystal structure communications
  • [ISO-abbreviation] Acta Crystallogr C
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Ligands; 0 / Organometallic Compounds; 0 / Polymers; 0 / poly(mu2-1,4-bis(imidazol-1-yl)benzene)(mu2-terephthalato)dizinc(II); J41CSQ7QDS / Zinc
  •  go-up   go-down


54. Lee MH, Lee WH, Todorov I, Liu CP: CD4+ CD25+ regulatory T cells prevent type 1 diabetes preceded by dendritic cell-dominant invasive insulitis by affecting chemotaxis and local invasiveness of dendritic cells. J Immunol; 2010 Aug 15;185(4):2493-501
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD4+ CD25+ regulatory T cells prevent type 1 diabetes preceded by dendritic cell-dominant invasive insulitis by affecting chemotaxis and local invasiveness of dendritic cells.
  • Development of type 1 diabetes (T1D) is preceded by invasive insulitis.
  • Using an adoptive transfer model and noninvasive imaging-guided longitudinal analyses, we found nTreg depletion did not affect systemic trafficking and tissue localization of diabetogenic CD4(+) BDC2.5 T (BDC) cells in recipient mice prior to development of T1D.
  • In addition, neither the initial expansion/activation of BDC cells nor the number of CD11c(+) or NK cells in islets and pancreatic lymph nodes were altered.
  • Unexpectedly, our results showed nTreg depletion led to accelerated invasive insulitis dominated by CD11c(+) dendritic cells (ISL-DCs), not BDC cells, which stayed in the islet periphery.
  • Compared with control mice, the phenotype of ISL-DCs and their ability to stimulate BDC cells did not change during invasive insulitis development.
  • [MeSH-major] Dendritic Cells / immunology. Diabetes Mellitus, Type 1 / immunology. Islets of Langerhans / immunology. T-Lymphocytes, Regulatory / immunology

  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20639483.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD11c; 0 / Chemokine CCL19; 0 / Chemokine CCL21; 0 / Interleukin-2 Receptor alpha Subunit
  •  go-up   go-down


55. Mi C, Lu H, Liu H: Surgical excision of sacral tumors assisted by occluding the abdominal aorta with a balloon dilation catheter: a report of 3 cases. Spine (Phila Pa 1976); 2005 Oct 15;30(20):E614-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: A report of 3 cases of upper sacral tumors excised by occluding the abdominal aorta with a balloon dilation catheter (BDC).
  • OBJECTIVE: To investigate the feasibilities of reducing intraoperative hemorrhage and improving the safety of surgical excision of sacral tumors assisted by occluding the abdominal aorta with a BDC.
  • However, until now and to our knowledge, no report on resection of sacral tumors assisted by occluding the abdominal aorta with a BDC is available.
  • METHODS: A BDC was used to occlude the abdominal aorta for 40-65 minutes in assisting with resection of upper sacral tumors in 3 cases.
  • CONCLUSION: To occlude the abdominal aorta with a BDC may effectively reduce intraoperative hemorrhage, thus assisting the surgeon in the complete and safe resection of upper sacral tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227879.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. He H, Yuan D, Ma H, Sun D, Zhang G, Zhou HC: Control over interpenetration in lanthanide-organic frameworks: synthetic strategy and gas-adsorption properties. Inorg Chem; 2010 Sep 6;49(17):7605-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two isostructural lanthanide-organic frameworks (1 and 2) with 2-fold interpenetrating nets have been synthesized based on 1,4-benzenedicarboxylic acid (H(2)BDC).
  • By application of an organic ligand with hindrance groups and a terminal chelating ligand to replace BDC and coordinated solvates, interpenetration has been effectively controlled.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20799732.001).
  • [ISSN] 1520-510X
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Vougo-Zanda M, Huang J, Anokhina E, Wang X, Jacobson AJ: Tossing and turning: guests in the flexible frameworks of metal(III) dicarboxylates. Inorg Chem; 2008 Dec 15;47(24):11535-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The structures of 2 and 3 have the same topological framework as the previously reported aluminum 1,4-benzenedicarboxylate (BDC), Al(OH)(C(8)H(4)O(4)).0.7C(8)H(6)O(4) (1).
  • The frameworks are built by interconnecting M-OH-M chains (M = Al, Ga) with BDC anions to form large diamond-shaped one-dimensional channels filled with additional H(2)BDC guest molecules occupying disordered positions in the channels.
  • Upon removal of H(2)BDC, other guest molecules such as H(2)O and pyridine can be inserted.
  • In this work, we present a study of the intercalation of aromatic guests (BDC and pyridine) into frameworks of 1-3 by liquid and vapor diffusion into the empty channels of 1 and by single-crystal-to-single-crystal solvothermal guest exchange for 2 and 3.
  • In the case of Al(OH)BDC and Ga(OH,F)BDC, two interconvertible, guest-concentration-dependent phases with different orientations of the pyridine guests have been observed, while only one pyridine orientation is found in Ga(OH)BDC.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18433098.001).
  • [ISSN] 1520-510X
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Gao Q, Gao WH, Zhang CY, Xie YB: Penta-aqua-(1H-benzimidazole-5,6-di-carboxyl-ato-κN)copper(II) penta-hydrate. Acta Crystallogr Sect E Struct Rep Online; 2008;64(Pt 7):m928

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Penta-aqua-(1H-benzimidazole-5,6-di-carboxyl-ato-κN)copper(II) penta-hydrate.
  • The title compound, [Cu(C(9)H(4)N(2)O(4))(H(2)O)(5)]·5H(2)O, contains one crystallographically independent Cu(II) atom and one 1H-benzimidazole-5,6-dicarboxyl-ate (bdc) ligand, along with five coordinated and five uncoordinated water mol-ecules.
  • The Cu(II) atom is six-coordinated by one N atom from the bdc ligand and five O atoms from water mol-ecules, giving an octa-hedral coordination geometry.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10186-91 [16798880.001]
  • [Cites] Acta Crystallogr A. 2008 Jan;64(Pt 1):112-22 [18156677.001]
  • [Cites] Angew Chem Int Ed Engl. 2007;46(19):3456-9 [17385774.001]
  • (PMID = 21202783.001).
  • [ISSN] 1600-5368
  • [Journal-full-title] Acta crystallographica. Section E, Structure reports online
  • [ISO-abbreviation] Acta Crystallogr Sect E Struct Rep Online
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2961800
  •  go-up   go-down


59. Lee MH, Lee WH, Van Y, Contag CH, Liu CP: Image-guided analyses reveal that non-CD4 splenocytes contribute to CD4+ T cell-mediated inflammation leading to islet destruction by altering their local function and not systemic trafficking patterns. Mol Imaging; 2007 Nov-Dec;6(6):369-83
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recruitment of CD4(+) T cells into islets is a critical component of islet inflammation (insulitis) leading to type 1 diabetes; therefore, determining if conditions used to treat diabetes change their trafficking patterns is relevant to the outcome.
  • Cotransfer of CD4(+)BDC2.5 (BDC) cells with non-CD4 splenocytes obtained from newly diabetic NOD mice, but not when they are transferred alone, induces accelerated diabetes.
  • It is unclear whether these splenocytes affect diabetes development by altering the systemic and/or local trafficking and proliferation patterns of BDC cells in target and nontarget tissues.
  • To address these questions, we developed an animal model to visualize BDC cell trafficking and proliferation using whole-body in vivo bioluminescence imaging and used the images to direct tissue sampling for further analyses of the cell distribution within tissues.
  • Taken together, the non-CD4 splenocytes act locally by promoting invasive insulitis without altering the systemic trafficking patterns or proliferation of BDC cells and thus contributing to diabetes by altering the localization within the tissue.
  • [MeSH-minor] Animals. Cell Death / immunology. Diabetes Mellitus, Type 1 / etiology. Flow Cytometry. Image Processing, Computer-Assisted. Luciferases / genetics. Luciferases / metabolism. Luminescent Proteins / metabolism. Mice. Mice, Inbred NOD. Mice, Transgenic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18053408.001).
  • [ISSN] 1535-3508
  • [Journal-full-title] Molecular imaging
  • [ISO-abbreviation] Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Luminescent Proteins; EC 1.13.12.- / Luciferases
  •  go-up   go-down


60. Meng Q, Wang L, Liu Y, Pang Y: catena-Poly[[bis-(1H-benzimidazole-κN)palladium(II)]-μ-benzene-1,4-dicarboxyl-ato-κO:O]. Acta Crystallogr Sect E Struct Rep Online; 2007;64(Pt 1):m133
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the title compound, [Pd(C(8)H(4)O(4))(C(7)H(6)N(2))(2)](n), the Pd atom is tetra-coordinated by two carboxyl-ate O atoms from two benzene-1,4-dicarboxyl-ate (bdc) dianions and two N atoms from two benzimidazole ligands, resulting in a slightly distorted tetra-hedral PdO(2)N(2) geometry.
  • The bdc ligand acts as a bridge, linking the Pd atoms into a chain.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Crystallogr C. 2000 Dec;56(Pt 12):1416-7 [11118970.001]
  • [RetractionIn] Acta Crystallogr Sect E Struct Rep Online. 2012 Jul 1;68(Pt 7):e14-5 [22807693.001]
  • (PMID = 21200490.001).
  • [ISSN] 1600-5368
  • [Journal-full-title] Acta crystallographica. Section E, Structure reports online
  • [ISO-abbreviation] Acta Crystallogr Sect E Struct Rep Online
  • [Language] eng
  • [Publication-type] Journal Article; Retracted Publication
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2915081
  •  go-up   go-down


61. Milhoua PM, Koi PT, Hakimi AA, Li M, Ghavamian R: Laparoscopic nephrectomy for the management of renal medullary carcinoma in a child. J Pediatr Urol; 2008 Feb;4(1):90-2
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic nephrectomy for the management of renal medullary carcinoma in a child.
  • Renal medullary carcinoma is a lethal subtype of renal cancer that afflicts patients with sickle-cell hemoglobinopathies.
  • Here we present the case of a 13-year-old boy with renal medullary carcinoma who is the first, to our knowledge, to be managed using a planned laparoscopic radical nephrectomy.
  • [MeSH-major] Kidney Medulla. Kidney Neoplasms / surgery. Laparoscopy. Nephrectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18631900.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


62. Kong ZG, Wang M, Ma XY, Wang QW: catena-Poly[[aqua(11-chloropyrido[2',3':2,3]pyrimidino[5,6-f][1,10]phenanthroline-kappa2N4,N5)cadmium(II)]-mu-benzene-1,4-dicarboxylato-kappa3O1,O1':O4]: an inclined interpenetrating (6,3) network. Acta Crystallogr C; 2009 Dec;65(Pt 12):m472-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The asymmetric unit of the title compound, [Cd(C(8)H(4)O(4))(C(17)H(8)ClN(5))(H(2)O)](n), contains one Cd(II) atom, two half benzene-1,4-dicarboxylate (1,4-bdc) anions, one 11-chloropyrido[2',3':2,3]pyrimidino[5,6-f][1,10]phenanthroline (L) ligand and one coordination water molecule.
  • The 1,4-bdc ligands are on inversion centers at the centroids of the arene rings.
  • The Cd(II) atom is six-coordinated by two N atoms from one L ligand, three carboxylate O atoms from two different 1,4-bdc ligands and one water O atom in a distorted octahedral coordination sphere.
  • Each Cd(II) center is bridged by the 1,4-bdc dianions to give a one-dimensional chain.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19966430.001).
  • [ISSN] 1600-5759
  • [Journal-full-title] Acta crystallographica. Section C, Crystal structure communications
  • [ISO-abbreviation] Acta Crystallogr C
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


63. Bárcia PS, Zapata F, Silva JA, Rodrigues AE, Chen B: Kinetic separation of hexane isomers by fixed-bed adsorption with a microporous metal-organic framework. J Phys Chem B; 2007 Jun 7;111(22):6101-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A three-dimensional microporous metal-organic framework Zn(BDC)(Dabco)0.5 (BDC = 1,4-benzenedicarboxylate, Dabco = 1,4-diazabicyclo [2,2,2]octane), having two types of intersecting pores to encapsulate linear hexane and to block branched hexanes, and thus exhibiting highly selective sorption with respect to n-hexane, has been successfully applied to the kinetic separation of hexane isomers by fixed-bed adsorption.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17500557.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  •  go-up   go-down


64. Muda P, Kampus P, Teesalu R, Zilmer K, Ristimäe T, Fischer K, Zilmer M: Effects of amlodipine and candesartan on oxidized LDL level in patients with mild to moderate essential hypertension. Blood Press; 2006;15(5):313-8
Hazardous Substances Data Bank. AMLODIPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To compare the effects of amlodipine and candesartan on oxidized low-density lipoprotein (OxLDL), conjugated dienes (CD) and baseline diene conjugation in circulating low-density lipoproteins (LDL-BDC) level during antihypertensive treatment.
  • Blood pressure, OxLDL, CD, LDL-BDC, triglycerides (TG), total cholesterol and lipoprotein cholesterol were measured at baseline, at week 2 and at week 16.
  • At the same time serum TG, lipoprotein and total cholesterol levels as well as LDL-BDC did not change and CD levels did not exceed endemic normal.
  • Decrease in both systolic and diastolic blood pressure was associated with decrease in LDL-BDC/LDL.

  • Genetic Alliance. consumer health - Essential hypertension.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • Hazardous Substances Data Bank. CANDESARTAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17380850.001).
  • [ISSN] 0803-7051
  • [Journal-full-title] Blood pressure
  • [ISO-abbreviation] Blood Press.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Alkenes; 0 / Benzimidazoles; 0 / Lipids; 0 / Lipoproteins, LDL; 0 / Tetrazoles; 0 / oxidized low density lipoprotein; 1J444QC288 / Amlodipine; S8Q36MD2XX / candesartan
  •  go-up   go-down


65. Narbutt J, Lesiak A, Sysa-Jedrzejowska A, Smolewski P, Robak T, Zalewska A: The number and distribution of blood dendritic cells in the epidermis and dermis of healthy human subjects. Folia Histochem Cytobiol; 2006;44(1):61-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human blood dendritic cells (BDC) can be divided into three subsets: plasmacytoid DC (PDC) and two myeloid subsets--MDC1 and MDC2.
  • Several studies revealed the presence of both MDC and PDC in blood of healthy subjects, however no precise literature data exist on the number and distribution of BDC in the skin.
  • The aim of our study was to assess the number and distribution of BDC and their subtypes in the healthy skin.
  • Punch biopsies were taken from the buttock skin from each subject, and immunofluorescent staining was performed using monoclonal mouse IgG1 antibodies directed against BDCA-1, BDCA-2, BDCA-3 and BDC-4.
  • The BDC were present both in the epidermis and dermis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16584094.001).
  • [ISSN] 0239-8508
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  •  go-up   go-down


66. Liu XG, Huang J, Bao SS, Li YZ, Zheng LM: Homochiral zinc phosphonates with layered and open framework structures using polycarboxylate as second linkers. Dalton Trans; 2009 Nov 28;(44):9837-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reactions of zinc sulfate and (R)- or (S)-(1-phenylethylamino)methylphosphonic acid (pempH(2)) in the presence of 1,4-benzenedicarboxylic acid (H(2)bdc) result in homochiral enantiomers (R)- and (S)-[Zn(4)(pempH)(4)(bdc)(2)].2H(2)O ().
  • When H(2)bdc is replaced by 1,2,4,5-benzenetetracarboxylic acid (H(4)btec), enantiomers (R)- and (S)-[Zn(3)(pempH)(2)(btec)(H(2)O)(2)].H(2)O () are obtained.
  • Compounds have a layer structure in which the chiral inorganic double chains, made up of corner-sharing {ZnO(4)} and {PO(3)C} tetrahedra, are connected by bdc(2-).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19885531.001).
  • [ISSN] 1477-9234
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Cheng JW, Zheng ST, Ma E, Yang GY: {Ln(III)[mu(5)-kappa(2),kappa(1),kappa(1),kappa(1),kappa(1)-1,2-(CO2)(2)C6H4][isonicotine][H2O]}(2)Cu(I) x X (Ln = Eu, Sm, Nd; X = ClO4-, Cl-): a new pillared-layer approach to heterobimetallic 3d-4f 3d-network solids. Inorg Chem; 2007 Dec 10;46(25):10534-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A new series of heterometallic lanthanide(III)-copper(I) coordination polymers Ln2(bdc)2(ina)2(H2O)2Cu x X (Hina = isonicotinic acid; H2bdc = 1,2-benzenedicarboxylic acid; Ln = Eu (1), Sm (2), Nd (3), X = ClO4-; Ln = Nd (4), X = Cl-) have been hydrothermally synthesized in the presence/absence of HClO4.
  • Both compounds are isostructural and contained two distinct units of 2D Ln-bdc layers and linear [Cu(ina)2]-.
  • The linear [Cu(ina)2]- complexes act as pillars and further link the Ln-bdc layers resulting in four heterometallic metal-organic frameworks, which represent the first pillared-layer 3d-4f framework with two distinct types of channels along the b and c axes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17990870.001).
  • [ISSN] 0020-1669
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Zou L, Mendez F, Martin-Orozco N, Peterson EJ: Defective positive selection results in T cell lymphopenia and increased autoimmune diabetes in ADAP-deficient BDC2.5-C57BL/6 mice. Eur J Immunol; 2008 Apr;38(4):986-94
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adhesion and degranulation promoting adapter protein (ADAP), a positive regulator of T cell receptor (TCR) signaling, is required for thymocyte development and T cell homeostasis.
  • To investigate the role of ADAP in a T cell-driven autoimmune response, we generated ADAP-deficient, BDC2.5 TCR transgenic, diabetes-prone (C57BL/6) mice (BDC/B6).
  • We observed a striking enhancement of diabetes incidence in ADAP-deficient mice, both in animals homozygous for I-Ag7, and in mice carrying one I-Ab allele (BDC/B6g7/b).
  • Consistent with a state of functional lymphopenia in ADAP-deficient BDC/B6g7/b mice, T cells display increased homeostatic proliferation.
  • Marked attenuation in cellularity of the CD4+ single-positive thymocyte compartment in ADAP-deficient BDC/B6g7/b animals suggests a mechanism for induction of the lymphopenia.
  • We conclude that inefficient positive selection in ADAP deficiency results in lymphopenia that leads to enhanced autoimmune diabetes in the BDC/B6g7/b model.

  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2001 Mar 1;166(5):3008-18 [11207250.001]
  • [Cites] Science. 2001 Sep 21;293(5538):2260-3 [11567140.001]
  • [Cites] Eur J Immunol. 1989 May;19(5):889-95 [2661244.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14580-5 [15340148.001]
  • [Cites] J Exp Med. 2004 Jun 7;199(11):1479-89 [15184501.001]
  • [Cites] Cell. 2004 Apr 16;117(2):265-77 [15084263.001]
  • [Cites] J Immunol. 2003 Dec 15;171(12):6954-60 [14662903.001]
  • [Cites] Immunol Rev. 2003 Apr;192:113-21 [12670399.001]
  • [Cites] Annu Rev Immunol. 2003;21:139-76 [12414722.001]
  • [Cites] Immunity. 2002 Dec;17(6):725-36 [12479819.001]
  • [Cites] Curr Opin Immunol. 2002 Jun;14(3):317-22 [11973129.001]
  • [Cites] Nat Immunol. 2001 Dec;2(12):1117-25 [11713466.001]
  • [Cites] Nat Immunol. 2001 Nov;2(11):1025-31 [11668341.001]
  • [Cites] Science. 2001 Sep 21;293(5538):2263-5 [11567141.001]
  • [Cites] Cell. 1993 Sep 24;74(6):1089-100 [8402882.001]
  • [Cites] Cell. 1996 May 3;85(3):291-7 [8616883.001]
  • [Cites] J Exp Med. 1996 Aug 1;184(2):387-96 [8760792.001]
  • [Cites] J Biol Chem. 1997 May 2;272(18):11674-7 [9115214.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7493-8 [9207119.001]
  • [Cites] Immunity. 1997 Dec;7(6):873-83 [9430232.001]
  • [Cites] Mol Cell Biol. 2007 Jun;27(11):4070-81 [17403904.001]
  • [Cites] Curr Opin Immunol. 2007 Jun;19(3):320-6 [17433869.001]
  • [Cites] Science. 2007 May 4;316(5825):754-8 [17478723.001]
  • [Cites] Mol Cell Biol. 2006 Oct;26(19):7130-44 [16980616.001]
  • [Cites] Eur J Immunol. 2006 Aug;36(8):2003-12 [16821236.001]
  • [Cites] J Immunol. 2006 Jun 1;176(11):6681-9 [16709827.001]
  • [Cites] J Immunol. 2006 Jun 1;176(11):6553-9 [16709812.001]
  • [Cites] J Clin Invest. 2005 Dec;115(12):3517-26 [16294223.001]
  • [Cites] J Leukoc Biol. 2005 Sep;78(3):575-84 [15894586.001]
  • [Cites] Trends Immunol. 2005 Jan;26(1):5-8 [15629402.001]
  • [Cites] J Exp Med. 1999 Jan 18;189(2):331-9 [9892615.001]
  • [Cites] J Exp Med. 1998 Feb 2;187(3):379-87 [9449718.001]
  • (PMID = 18383041.001).
  • [ISSN] 0014-2980
  • [Journal-full-title] European journal of immunology
  • [ISO-abbreviation] Eur. J. Immunol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI056016; United States / NIAID NIH HHS / AI / AI1056016-01; United States / NIAID NIH HHS / AI / AI056016-01; United States / NCI NIH HHS / CA / R44 CA105605; United States / NCI NIH HHS / CA / R44 CA105605-03; United States / NIAID NIH HHS / AI / R01 AI056016-01; United States / NCI NIH HHS / CA / CA105605-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Fyb protein, mouse
  • [Other-IDs] NLM/ NIHMS178752; NLM/ PMC2829296
  •  go-up   go-down


69. Wagner AD, Buechner-Steudel P, Moehler M, Schmalenberg H, Behrens R, Fahlke J, Wein A, Behl S, Kuss O, Kleber G, Fleig WE: Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials. Br J Cancer; 2009 Dec 1;101(11):1846-52
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.
  • BACKGROUND: Gemcitabine, oxaliplatin and 5-fluorouracil (5-FU) are active in biliary tract cancer and have a potentially synergistic mode of action and non-overlapping toxicity.
  • The objective of these trials was to determine response, survival and toxicity separately in patients with bile duct cancer (BDC) and gallbladder cancer (GBC) treated with gemcitabine/oxaliplatin/5-FU chemotherapy.
  • METHODS: Eligible patients with histologically proven, advanced or metastatic BDC (n=37) or GBC (n=35) were treated with gemcitabine (900 mg m(-2) over 30 min), oxaliplatin (65 mg m(-2)) and 5-FU (1500 mg m(-2) over 24 h) on days 1 and 8 of a 21-day cycle.
  • RESULTS: Response rates were 19% (95% CI: 6-32%) and 23% (95% CI: 9-37%) for BDC and GBC, respectively.
  • Median survivals were 10.0 months (95% CI: 8.6-12.4) and 9.9 months (95% CI: 7.5-12.2) for BDC and GBC, respectively, and 1- and 2-year survival rates were 40 and 23% in BDC and 34 and 6% in GBC (intention-to-treat analysis).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Bile Duct Neoplasms / drug therapy. Gallbladder Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1998 Jun 15;82(12):2321-5 [9635523.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):593-600 [8879373.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):111-8 [15558814.001]
  • [Cites] Eur J Cancer. 2005 Feb;41(3):398-403 [15691639.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2332-8 [15800324.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1650-4 [15856037.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7753-4; author reply 7754-5 [16234545.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2004 Nov;1(1):4-5 [16265019.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1152-60 [16505435.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1339-46 [16475213.001]
  • [Cites] BMC Cancer. 2006;6:121 [16677397.001]
  • [Cites] Ann Oncol. 2007 Jan;18(1):82-7 [17030546.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):896-902 [17325704.001]
  • [Cites] Invest New Drugs. 2007 Aug;25(4):385-90 [17364234.001]
  • [Cites] Jpn J Clin Oncol. 2007 Nov;37(11):843-51 [17942578.001]
  • [Cites] Br J Cancer. 2008 Jan 29;98(2):418-25 [18087285.001]
  • [Cites] Br J Cancer. 2008 Jan 29;98(2):309-15 [18182984.001]
  • [Cites] Oncologist. 2008 Apr;13(4):415-23 [18448556.001]
  • [Cites] J Cancer Res Ther. 2008 Oct-Dec;4(4):151-5 [19052386.001]
  • [Cites] Ann Oncol. 2009 Jan;20(1):146-59 [18667395.001]
  • [Cites] Br J Cancer. 2008 Sep 16;99(6):862-7 [19238628.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3375-80 [11705850.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2229-39 [11980994.001]
  • [Cites] Ann Oncol. 2004 Mar;15(3):478-83 [14998852.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1339-43 [15319238.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Semin Oncol. 1995 Aug;22(4 Suppl 11):72-9 [7481849.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(2):117-23 [10412945.001]
  • (PMID = 19904267.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2788250
  •  go-up   go-down


70. Luo G, Johnson S, Hsueh MM, Zheng J, Cai H, Xin B, Chong S, He K, Harper TW: In silico prediction of biliary excretion of drugs in rats based on physicochemical properties. Drug Metab Dispos; 2010 Mar;38(3):422-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The bile duct-cannulated (BDC) rat model is commonly used to determine the percentage of dose excreted as intact parent into bile.
  • However, a study using BDC rats is time-consuming and cost-ineffective.
  • The compounds were given intravenously at <10 mg/kg to BDC rats, and bile was collected for at least 8 h after dosing.
  • In addition, biliary excretion was also highly corrected with the presence of a carboxylic acid moiety in the test compounds (r = 0.87).
  • [MeSH-minor] Animals. Bile Ducts. Carboxylic Acids / analysis. Carboxylic Acids / chemistry. Carboxylic Acids / pharmacokinetics. Catheters, Indwelling. Computational Biology. Least-Squares Analysis. Male. Models, Biological. Physicochemical Phenomena. Rats. Rats, Sprague-Dawley. Solubility. Surface Properties

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19995888.001).
  • [ISSN] 1521-009X
  • [Journal-full-title] Drug metabolism and disposition: the biological fate of chemicals
  • [ISO-abbreviation] Drug Metab. Dispos.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carboxylic Acids; 0 / Drugs, Investigational
  •  go-up   go-down


71. Müller M, Zhang X, Wang Y, Fischer RA: Nanometer-sized titania hosted inside MOF-5. Chem Commun (Camb); 2009 Jan 7;(1):119-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nanoscale titania particles were synthesized inside the porous coordination polymer [Zn(4)O(bdc)(3)] (bdc = 1,4-benzene-dicarboxylate, MOF-5) by adsorption of titanium isopropoxide from the gas-phase and subsequent dry oxidation and annealing.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19082018.001).
  • [ISSN] 1359-7345
  • [Journal-full-title] Chemical communications (Cambridge, England)
  • [ISO-abbreviation] Chem. Commun. (Camb.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


72. Xing XP, Wang XB, Wang LS: Photoelectron angular distribution and molecular structure in multiply charged anions. J Phys Chem A; 2009 Feb 12;113(6):945-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using photoelectron imaging, we observed the effects of ICR on photoelectron angular distributions (PAD) of the three isomers of benzene dicarboxylate dianions C6H4(CO2)2(2-) (o-, m- and p-BDC(2-)).
  • Photoelectrons were observed to peak along the laser polarization due to the ICR, but the anisotropy was the largest for p-BDC(2-), followed by the m- and o-isomer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19007194.001).
  • [ISSN] 1520-5215
  • [Journal-full-title] The journal of physical chemistry. A
  • [ISO-abbreviation] J Phys Chem A
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  •  go-up   go-down


73. Ravindran J, Subbaraju GV, Ramani MV, Sung B, Aggarwal BB: Bisdemethylcurcumin and structurally related hispolon analogues of curcumin exhibit enhanced prooxidant, anti-proliferative and anti-inflammatory activities in vitro. Biochem Pharmacol; 2010 Jun 1;79(11):1658-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found that bisdemethylcurcumin (BDC) was more potent than curcumin as an anti-inflammatory agent as indicated by suppression of TNF-induced NF-kappaB activation, more potent as an anti-proliferative agent, and more potent in inducing ROS.
  • When synthetic curcumin (Cur-S) was compared with bisdemethylcurcumin (BDC), hispolon, hispolon methyl ether (HME), dehydroxy hispolon (DH), hydroxy hispolon (HH), methoxy hispolon methyl ether (MHME), and methoxy hispolon (MH), we found that following order of anti-inflammatory activity: BDC=Hispolon>HME>HH>Cur-S>MHME>MH>DH; for anti-proliferative: Hispolon>BDC>MHME>Cur-S>MH>HME=HH>DH; and for prooxidant: BDC>Cur-S=MHME>HH>MH+HME>DH (254-1414 mean fluorescence intensity).
  • Overall the results indicate that the substitution of a hydroxyl group for a methoxy group at the meta positions of the phenyl rings in curcumin significantly enhanced the anti-inflammatory activity, and the removal of phenyl ring at the 7(th) position of the heptadiene back bone and addition of hydroxyl group significantly increased the anti-proliferative activity of curcumin.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CURCUMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • [Cites] AAPS J. 2009 Sep;11(3):495-510 [19590964.001]
  • [Cites] Trends Pharmacol Sci. 2009 Feb;30(2):85-94 [19110321.001]
  • [Cites] Methods Enzymol. 2000;319:585-602 [10907546.001]
  • [Cites] Matrix Biol. 2002 Apr;21(3):251-62 [12009331.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1A):363-98 [12680238.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):24233-41 [12711606.001]
  • [Cites] J Immunol. 2003 Oct 1;171(7):3863-71 [14500688.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):203-8 [15380510.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):813-9 [1899046.001]
  • [Cites] J Biol Chem. 1995 Oct 20;270(42):24995-5000 [7559628.001]
  • [Cites] Biochem Pharmacol. 1998 Jun 15;55(12):1955-62 [9714315.001]
  • [Cites] Antioxid Redox Signal. 2005 Jan-Feb;7(1-2):32-41 [15650394.001]
  • [Cites] Bioorg Med Chem. 2005 Dec 1;13(23):6374-80 [16112582.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1056:206-17 [16387689.001]
  • [Cites] J Ethnopharmacol. 2006 Apr 21;105(1-2):280-5 [16563677.001]
  • [Cites] Carcinogenesis. 2006 Oct;27(10):2008-17 [16613838.001]
  • [Cites] Exp Hematol. 2007 Jan;35(1):84-95 [17198877.001]
  • [Cites] J Clin Immunol. 2007 Jan;27(1):19-35 [17211725.001]
  • [Cites] Adv Exp Med Biol. 2007;595:1-75 [17569205.001]
  • [Cites] Free Radic Biol Med. 2007 Aug 15;43(4):568-80 [17640567.001]
  • [Cites] Curr Probl Cancer. 2007 Jul-Aug;31(4):243-305 [17645940.001]
  • [Cites] Carcinogenesis. 2007 Aug;28(8):1765-73 [17522064.001]
  • [Cites] Mol Pharm. 2007 Nov-Dec;4(6):807-18 [17999464.001]
  • [Cites] Free Radic Biol Med. 2008 Jul 1;45(1):60-72 [18423410.001]
  • [Cites] Cancer Lett. 2008 Oct 8;269(2):199-225 [18479807.001]
  • [Cites] Biochem Pharmacol. 2008 Dec 1;76(11):1590-611 [18775680.001]
  • [Cites] Int J Biochem Cell Biol. 2009 Jan;41(1):40-59 [18662800.001]
  • [Cites] Oncogene. 1999 Oct 28;18(44):6013-20 [10557090.001]
  • (PMID = 20138025.001).
  • [ISSN] 1873-2968
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-124787-01A2; United States / NCI NIH HHS / CA / P01 CA124787; United States / NCI NIH HHS / CA / P01 CA091844-020004; United States / NCI NIH HHS / CA / P01 CA091844; United States / NCI NIH HHS / CA / CA-16 672; United States / NCI NIH HHS / CA / CA124787-020002; United States / NCI NIH HHS / CA / CA091844-010004; United States / NCI NIH HHS / CA / P01 CA124787-01A20002; United States / NCI NIH HHS / CA / P01 CA091844-010004; United States / NCI NIH HHS / CA / CA091844-020004; United States / NCI NIH HHS / CA / CA124787-01A20002; United States / NCI NIH HHS / CA / P01 CA124787-020002
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents; 0 / Catechols; 0 / Reactive Oxygen Species; 0 / hispolon; IT942ZTH98 / Curcumin
  • [Other-IDs] NLM/ NIHMS183342; NLM/ PMC2846970
  •  go-up   go-down


74. Riener MO, Fritzsche FR, Soll C, Pestalozzi BC, Probst-Hensch N, Clavien PA, Jochum W, Soltermann A, Moch H, Kristiansen G: Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. Histopathology; 2010 Apr;56(5):600-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas.
  • AIMS: To study the relevance of periostin, known to be involved in epithelial-mesenchymal transition (EMT), in hepatocellular and bile duct cancer.
  • METHODS AND RESULTS: Immunohistochemical periostin expression was semiquantitatively analysed in normal liver tissue (n = 20), hepatocellular carcinoma (HCC; n = 91), liver-cell adenoma (n = 9), focal nodular hyperplasia (n = 13) and bile duct carcinomas (BDC; n = 116) using tissue microarrays.
  • Normal bile ducts, gallbladder epithelium and hepatocytes showed weak cytoplasmic periostin expression.
  • Strong stromal periostin expression was detected in 78/116 (67.2%) BDC and strong epithelial expression in 39/116 (33.6%) BDC. pT stage, differentiation grade and proliferation rate in primary BDC were independent of periostin expression.
  • CONCLUSIONS: The EMT protein periostin is expressed in the stroma and epithelium of a subset of BDC and HCC.
  • Epithelial periostin expression is a marker for malignant transformation of hepatocytes and a novel prognostic marker in BDC.
  • [MeSH-major] Adenoma / metabolism. Bile Duct Neoplasms / metabolism. Carcinoma, Hepatocellular / metabolism. Cell Adhesion Molecules / metabolism. Focal Nodular Hyperplasia / metabolism. Liver Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20459570.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / POSTN protein, human
  •  go-up   go-down


75. Sun J, Zhou Y, Fang Q, Chen Z, Weng L, Zhu G, Qiu S, Zhao D: Construction of 3D layer-pillared homoligand coordination polymers from a 2D layered precursor. Inorg Chem; 2006 Oct 16;45(21):8677-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • First, a layered metal-organic framework Zn3(BDC)3(H2O)2 x 4DMF 1 (BDC is terephthalate, DMF is N,N-dimethylformamide) was fabricated from a H2BDC by liquid-liquid diffusion.
  • Second, the layered product, 1, was used as a precursor to solvothermally react with further H2BDC at 140-180 degrees C, resulting in two products of BDC insertion into the layered structure.
  • These are [Zn3(p-BDC)4] x 2HPIP, 2 (HPIP is partly protonated piperazine), and [Zn3(p-BDC)3(H2BDC)] x (C6H15NO) x H2O x 3DMF, 3 (C6H15NO is triethylamine N-oxide).
  • Single-crystal X-ray diffraction shows that 2 possesses a layer-pillared structure of mu4-BDC, with 1D channels, while 3 has a layer-pillared structure of mu2-BDC, with 2D channels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17029379.001).
  • [ISSN] 0020-1669
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Mabrut JY, Bozio G, Hubert C, Gigot JF: Management of congenital bile duct cysts. Dig Surg; 2010;27(1):12-8
Genetic Alliance. consumer health - Bile Duct Cysts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of congenital bile duct cysts.
  • Bile duct cysts (BDC) are rare congenital anomalies of the biliary tree that are characterized by cystic dilatation of the extrahepatic and/or intrahepatic bile ducts.
  • BDC are associated with biliary stasis and lithiasis, and the whole biliary epithelium is considered at risk of malignant transformation.
  • Complete cyst excision with cholecystectomy followed by biliary reconstruction using a Roux-en-Y hepatico-jejunostomy is the treatment of choice for the extrahepatic component of the disease (type I and IV BDC), but cystic involvement up to the roof of the main biliary convergence represents a real surgical challenge to perform complete resection.
  • The optimal treatment of intrahepatic bile duct dilatations remains controversial, especially for type IV-A BDC.
  • In type V BDC (Caroli's disease), extent of the liver resection is tailored to intrahepatic disease extent and takes into consideration the presence and severity of underlying chronic liver (congenital hepatic fibrosis) and kidney disease.
  • [MeSH-minor] Adult. Anastomosis, Roux-en-Y. Cholangiopancreatography, Magnetic Resonance. Female. Humans. Infant, Newborn. Jejunum / surgery. Liver / surgery. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20357446.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


77. Wilkinson R, Kassianos AJ, Swindle P, Hart DN, Radford KJ: Numerical and functional assessment of blood dendritic cells in prostate cancer patients. Prostate; 2006 Feb 1;66(2):180-92
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Numerical and functional assessment of blood dendritic cells in prostate cancer patients.
  • BACKGROUND: Prostate cancer is one of the leading causes of cancer deaths in males and there are currently no effective treatments available for metastatic disease.
  • We have undertaken the first detailed analysis of blood DC (BDC) subsets and their function in prostate cancer patients, with a view to utilizing immunoselected BDC for immunotherapy.
  • METHODS: We enumerated the CD11c+CD1c+, CD11c+CD16+, and CD11c-CD123+ BDC subsets in whole blood of prostate cancer patients using a single platform TruCOUNT assay.
  • The prostate cancer patients BDC had similar levels of key costimulatory molecules and cytokine expression profiles, compared to healthy donors, and these were upregulated to the same extent, in response to exogenous stimuli.
  • BDC from both groups were capable of eliciting allogeneic proliferative responses and inducing autologous CD4+ responses to naïve and recall antigens, and antigen-specific CD8+ responses to influenza matrix protein and prostate specific antigen.
  • CONCLUSIONS: These results indicate that an immunoselected CD1c+ BDC preparation could provide a suitable vaccine delivery vehicle for future prostate cancer immunotherapy trials.

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16173035.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Cytokines; 0 / Histocompatibility Antigens Class I; 0 / Histocompatibility Antigens Class II
  •  go-up   go-down


78. El-Watidy S: Bifrontal decompressive craniotomy in a 6-month-old infant with posttraumatic refractory intracranial hypertension. Pediatr Neurosurg; 2005 May-Jun;41(3):151-4
Genetic Alliance. consumer health - Intracranial Hypertension.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To document the outcome of bifrontal decompressive craniotomy (BDC) in an infant who developed refractory intracranial hypertension (IH) and massive brain infarction following severe head injury.
  • INTERVENTION: She had BDC and duraplasty carried out 8 h after admission.
  • CONCLUSION: BDC can be a life-saving procedure for infants with refractory IH and massive brain infarction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15995334.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


79. Sano T, Shimada K, Sakamoto Y, Ojima H, Esaki M, Kosuge T: Prognosis of perihilar cholangiocarcinoma: hilar bile duct cancer versus intrahepatic cholangiocarcinoma involving the hepatic hilus. Ann Surg Oncol; 2008 Feb;15(2):590-9
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of perihilar cholangiocarcinoma: hilar bile duct cancer versus intrahepatic cholangiocarcinoma involving the hepatic hilus.
  • BACKGROUND: Clinically hepatobiliary resection is indicated for both hilar bile duct cancer (BDC) and intrahepatic cholangiocarcinoma involving the hepatic hilus (CCC).
  • The aim of this study was to compare the long-term outcome of BDC and CCC.
  • RESULTS: The overall 3-year survival rate, 5-year survival rate, and median survival time for BDC patients were 48.4%, 38.4 %, and 33.7 months, respectively, and 35.8%, 24.5 %, and 22.7 months, respectively, in CCC patients (P = .033).
  • On multivariate analysis, three independent factors were related to longer survival in BDC patients: achieved in curative resection with cancer free margin (R0) (P = .024, odds ratio 1.862), well differentiated or papillary adenocarcinoma (P = .011, odds ratio 2.135), and absence of lymph node metastasis (P < .001, odds ratio 3.314).
  • Five factors were related to longer survival in CCC patients: absence of intrahepatic daughter nodules (P < .001, odds ratio 2.318), CEA level </=2.9 ng/mL (P = .005, odds ratio 2.606), no red blood cell transfusion requirement (P = .016, odds ratio 2.614), absence or slight degree of lymphatic system invasion (P < .001, odds ratio 4.577), and negative margin of the proximal bile duct (P = .003, odds ratio 7.398).
  • CONCLUSIONS: BDC and CCC appear to have different prognoses after hepatobiliary resection.
  • [MeSH-major] Bile Duct Neoplasms / mortality. Bile Ducts, Intrahepatic. Cholangiocarcinoma / mortality

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18057991.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


80. Riener MO, Stenner F, Liewen H, Soll C, Breitenstein S, Pestalozzi BC, Samaras P, Probst-Hensch N, Hellerbrand C, Müllhaupt B, Clavien PA, Bahra M, Neuhaus P, Wild P, Fritzsche F, Moch H, Jochum W, Kristiansen G: Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology; 2009 May;49(5):1602-9
Zurich Open Access Repository and Archive. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas.
  • Hepatocellular carcinomas (HCCs) and bile duct carcinomas (BDCs) have a poor prognosis.
  • Using tissue microarrays and immunohistochemistry, we semiquantitatively analyzed GOLPH2 protein expression in patients with HCC (n = 170), benign liver tumors (n = 22), BDC (n = 114) and normal liver tissue (n = 105).
  • A newly designed sandwich enzyme-linked immunoassay (ELISA) was used to analyze GOLPH2 levels in the sera of patients with HCC (n = 62), hepatitis C virus (HCV) (n = 29), BDC (n = 10), and healthy control persons (n = 12).
  • Serum levels of GOLPH2 measured by ELISA were significantly elevated in patients with HCC with underlying HCV infection (median 18 mg/L, P < 0.05) and patients with BDC (median = 14.5 mg/L, P < 0.01) in comparison to healthy controls (median 4 mg/L).
  • CONCLUSION: GOLPH2 protein is highly expressed in tissues of HCC and BDC.
  • GOLPH2 should be further evaluated as a serum tumor marker in BDC on a larger scale.
  • [MeSH-major] Adenoma, Liver Cell / metabolism. Bile Duct Neoplasms / metabolism. Carcinoma, Hepatocellular / metabolism. Focal Nodular Hyperplasia / metabolism. Liver Neoplasms / metabolism. Membrane Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bile Ducts / pathology. Biomarkers, Tumor / blood. Enzyme-Linked Immunosorbent Assay. Hepatitis, Chronic / blood. Humans. Middle Aged. Tissue Array Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hepatology. 2009 Jul;50(1):325 [19492428.001]
  • [CommentIn] Hepatology. 2009 Jul;50(1):326 [19496179.001]
  • [CommentIn] Hepatology. 2009 May;49(5):1421-3 [19402061.001]
  • [CommentIn] Hepatology. 2009 Nov;50(5):1682 [19739256.001]
  • (PMID = 19291786.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GOLM1 protein, human; 0 / Membrane Proteins
  •  go-up   go-down


81. Mabrut JY, Partensky C, Gouillat C, Baulieux J, Ducerf C, Kestens PJ, Boillot O, de la Roche E, Gigot JF: Cystic involvement of the roof of the main biliary convergence in adult patients with congenital bile duct cysts: a difficult surgical challenge. Surgery; 2007 Feb;141(2):187-95
Genetic Alliance. consumer health - Bile Duct Cysts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic involvement of the roof of the main biliary convergence in adult patients with congenital bile duct cysts: a difficult surgical challenge.
  • BACKGROUND: Complete cyst excision of the extrahepatic disease component with biliary reconstruction on proximal healthy bile ducts is considered to be the treatment of choice in patients with congenital bile duct cysts (BDC).
  • METHODS: A retrospective multicenter study was conducted in 4 European surgical centers concerning their experience with adult patients suffering from type I and IV BDC according to the Todani classification.
  • Clinical presentation, operative management, and postoperative outcome were compared between patients with or without proximal extrahepatic cystic disease that involved at least the roof of the MBC (defined as being BDC with MBC involvement subgroup).
  • RESULTS: From an overall series of 49 adult patients suffering from type I or IV BDC according to the Todani classification, 7 patients had BDC with MBC involvement (14%).
  • Patient age, clinical presentation, duration of symptoms, associated major coexistent hepatobiliary and pancreatic diseases, and synchronous cancer were not significantly different in these patients compared with a control group of 42 adult patients with BDC without MBC involvement.
  • Incomplete proximal cyst excision rate was 86% in the cases of BDC with MBC involvement.
  • Early and late postoperative results were similar in BDC with MBC involvement and in the control group of adult patients, but the incidence of subsequent cancer was significantly higher in the BDC with MBC involvement group (29% vs 0%; P < .02).
  • CONCLUSION: BDC that involves the roof of the MBC is a real surgical challenge to obtain complete proximal cystic disease excision.
  • As suggested in this small study, primary incomplete excision of this particular form of BDC might expose the patient to the risk of subsequent cancer, a feature that must be confirmed in larger series.
  • [MeSH-major] Bile Ducts, Extrahepatic / pathology. Bile Ducts, Extrahepatic / surgery. Choledochal Cyst / pathology. Choledochal Cyst / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17263975.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


82. Al-Assaf K, Chakmakchi M, Palaghias G, Karanika-Kouma A, Eliades G: Interfacial characteristics of adhesive luting resins and composites with dentine. Dent Mater; 2007 Jul;23(7):829-39

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: The products tested were Bistite II DC (BDC), C&B Super-Bond (CBM), M-Bond (MBD), Panavia-F (PAF) and Rely-X Unicem (RXU).
  • RESULTS: TBS (MPa) values were BDC (13.01), MBD (9.19) and PAF (7.07) significantly different from CBM (4.79) and RXU (4.47).
  • The percentage of debonded dentine area covered with resin showed the highest values in BDC (47.80) and MBD (38.12) significantly different from CBM (17.20), PAF (16.47), and RXU (16.50).
  • No statistical differences were found among BDC (60.86%), MBD (60.22%) and PAF (51.99%).
  • CBM induced the most pronounced tubule funneling and intertubular dissolution, followed by PAF, BDC and MDB.
  • No statistically significant differences were found between PAF (0.95microm) and BDC (1.12microm), whereas RXU showed no detectable hybrid layer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16934865.001).
  • [ISSN] 0109-5641
  • [Journal-full-title] Dental materials : official publication of the Academy of Dental Materials
  • [ISO-abbreviation] Dent Mater
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dentin-Bonding Agents; 0 / Resin Cements
  •  go-up   go-down


83. Fu GH: Poly[tetra-aqua-bis-(μ(3)-benzene-1,3-di-carboxyl-ato-κO:O':O'')bis-(μ(2)-benzene-1,3-dicarboxyl-ato-κO,O':O'')[μ(2)-1,4-bis-(1,2,4-triazol-1-yl)butane-κN:N']tetra-zinc(II)]. Acta Crystallogr Sect E Struct Rep Online; 2010;67(Pt 1):m73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poly[tetra-aqua-bis-(μ(3)-benzene-1,3-di-carboxyl-ato-κO:O':O'')bis-(μ(2)-benzene-1,3-dicarboxyl-ato-κO,O':O'')[μ(2)-1,4-bis-(1,2,4-triazol-1-yl)butane-κN:N']tetra-zinc(II)].
  • In the crystal structure of the title compound, [Zn(4)(C(8)H(4)O(4))(4)(C(8)H(12)N(6))(H(2)O)(4)](n), one Zn(II) atom is four-coordinated in a slightly distorted tetra-hedral geometry by two O atoms from benzene-1,3-dicarboxyl-ate (BDC) ligands, one N atom from a 1,4-bis-(1,2,4-triazol-1-yl)butane (BTB) ligand and one water mol-ecule, while a second Zn(II) atom is five-coordinated in a distorted square-pyramidal geometry bridged by four O atoms from BDC ligands and one water mol-ecule.
  • The asymmetric unit consits of two crystallographically independent Zn(II) cations, two BDC anions and two water mol-ecules in general positions, as well as one-half of the BTB ligand that is completed by inversion symmetry.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Angew Chem Int Ed Engl. 2009;48(29):5291-5 [19536803.001]
  • [Cites] Acta Crystallogr A. 2008 Jan;64(Pt 1):112-22 [18156677.001]
  • (PMID = 21522591.001).
  • [ISSN] 1600-5368
  • [Journal-full-title] Acta crystallographica. Section E, Structure reports online
  • [ISO-abbreviation] Acta Crystallogr Sect E Struct Rep Online
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3050338
  •  go-up   go-down


84. Hausdorf S, Wagler J, Mossig R, Mertens FO: Proton and water activity-controlled structure formation in zinc carboxylate-based metal organic frameworks. J Phys Chem A; 2008 Aug 21;112(33):7567-76

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The contributions of terephthalic acid and Zn(2+)-coordinated water in N,N-diethylformamide (DEF) to the overall proton activity in the synthesis of MOF-5 (Zn4O(BDC)3, BDC = 1,4-benzenedicarboxylate) were quantitatively determined by combined electrochemical and UV-vis spectroscopic measurements.
  • It was found that the water-induced structural transition of MOF-5 to the hydroxide structure Zn3(OH)2(BDC)2 x 2 DEF (MOF-69c) can be reverted by a thermal treatment of the obtained compound and its subsequent exposure to anhydrous DEF.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18652430.001).
  • [ISSN] 1520-5215
  • [Journal-full-title] The journal of physical chemistry. A
  • [ISO-abbreviation] J Phys Chem A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Cot SS, So AK, Espie GS: A multiprotein bicarbonate dehydration complex essential to carboxysome function in cyanobacteria. J Bacteriol; 2008 Feb;190(3):936-45
Hazardous Substances Data Bank. Carbon dioxide .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using biochemical activity assays and molecular approaches we have identified a catalytic, multiprotein HCO3- dehydration complex (BDC) associated with the protein shell of Synechocystis carboxysomes.
  • The complex was minimally composed of a CcmM73 trimer, CcaA dimer, and CcmN.
  • Yeast two-hybrid analyses indicated that the BDC was associated with the carboxysome shell through CcmM73-specific protein interactions with CcmK and CcmL.
  • The specificity of the CcmM73-CcaA interaction provided both a mechanism to integrate CcaA into the fabric of the carboxysome shell and a means to recruit this enzyme to the BDC during carboxysome biogenesis.
  • Functionally, CcaA was the catalytic core of the BDC.
  • CcmM73 bound H14CO3- but was unable to catalyze HCO3- dehydration, suggesting that it may potentially regulate BDC activity.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D237-40 [17135202.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18368-73 [17116880.001]
  • [Cites] Methods Enzymol. 1972;25:579-84 [23014442.001]
  • [Cites] J Mol Biol. 2007 Sep 21;372(3):764-73 [17669419.001]
  • [Cites] Planta. 2002 Jan;214(3):456-67 [11859847.001]
  • [Cites] J Exp Bot. 2003 Feb;54(383):609-22 [12554704.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3381-5 [12824332.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):16107-12 [14673118.001]
  • [Cites] J Bacteriol. 2004 Feb;186(3):623-30 [14729686.001]
  • [Cites] Protein Eng Des Sel. 2004 Mar;17(3):285-91 [15051865.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W590-4 [15215457.001]
  • [Cites] Methods Enzymol. 1982;87:732-52 [6294458.001]
  • [Cites] J Bacteriol. 1989 Nov;171(11):6069-76 [2509426.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4437-41 [1584776.001]
  • [Cites] J Bacteriol. 1993 May;175(10):2871-9 [8491708.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6909-13 [8041719.001]
  • [Cites] EMBO J. 1996 May 15;15(10):2323-30 [8665839.001]
  • [Cites] DNA Res. 1996 Jun 30;3(3):109-36 [8905231.001]
  • [Cites] Plant Mol Biol. 1998 May;37(2):205-15 [9617794.001]
  • [Cites] Annu Rev Plant Biol. 2005;56:99-131 [15862091.001]
  • [Cites] Science. 2005 Aug 5;309(5736):936-8 [16081736.001]
  • [Cites] J Exp Bot. 2006;57(2):249-65 [16216846.001]
  • [Cites] J Mol Biol. 2000 Jun 2;299(2):499-520 [10860755.001]
  • [Cites] Biochemistry. 2000 Aug 8;39(31):9222-31 [10924115.001]
  • [Cites] Appl Environ Microbiol. 2001 Dec;67(12):5351-61 [11722879.001]
  • [Cites] J Biol Chem. 2006 Mar 17;281(11):7546-55 [16407248.001]
  • [Cites] Biochemistry. 2006 Apr 11;45(14):4351-61 [16584170.001]
  • [Cites] J Mol Biol. 2006 Dec 1;364(3):526-35 [17028023.001]
  • [Cites] PLoS Biol. 2007 Jun;5(6):e144 [17518518.001]
  • (PMID = 17993516.001).
  • [ISSN] 1098-5530
  • [Journal-full-title] Journal of bacteriology
  • [ISO-abbreviation] J. Bacteriol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Bicarbonates; 0 / Multiprotein Complexes; 142M471B3J / Carbon Dioxide; EC 4.1.1.39 / Ribulose-Bisphosphate Carboxylase
  • [Other-IDs] NLM/ PMC2223583
  •  go-up   go-down


86. Calderon B, Suri A, Pan XO, Mills JC, Unanue ER: IFN-gamma-dependent regulatory circuits in immune inflammation highlighted in diabetes. J Immunol; 2008 Nov 15;181(10):6964-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diabetogenic CD4(+)BDC2.5 (BDC) T cell clone upon transfer into NOD.scid mice induced destruction of islets of Langerhans leading to diabetes.
  • Administration of a neutralizing Ab to IFN-gamma (H22) resulted in long-term protection (LTP) from diabetes, with inflammation but persistence of a significant, albeit decreased, number of beta cells.
  • BDC T cells were a mixture of cells expressing high, intermediate, and low levels of the TCR.
  • Clonotype(low) BDC T cells were required for LTP.
  • Gene expression profiles indicated that macrophages in diabetic mice were M1 type, while LTP mice contained M2 differentiated.
  • Transfer of only clonotype(high)-expressing BDC T cells induced diabetes; in contrast, H22 Abs did not inhibit diabetes.

  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 1;89(9):3927-31 [1570315.001]
  • [Cites] Nat Rev Immunol. 2004 Oct;4(10):762-74 [15459668.001]
  • [Cites] J Immunol. 1994 May 15;152(10):5084-91 [8176224.001]
  • [Cites] Cell. 1996 May 3;85(3):291-7 [8616883.001]
  • [Cites] Diabetes. 1996 Jun;45(6):812-7 [8635658.001]
  • [Cites] Endocrinology. 1996 Dec;137(12):5567-75 [8940385.001]
  • [Cites] Annu Rev Immunol. 1997;15:563-91 [9143700.001]
  • [Cites] J Biol Chem. 1997 May 23;272(21):13697-704 [9153221.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13844-9 [9391115.001]
  • [Cites] J Exp Med. 1999 Apr 5;189(7):1053-62 [10190896.001]
  • [Cites] Immunol Rev. 1999 Jun;169:55-65 [10450508.001]
  • [Cites] Eur J Immunol. 2004 Nov;34(11):2996-3005 [15468055.001]
  • [Cites] Trends Immunol. 2004 Dec;25(12):677-86 [15530839.001]
  • [Cites] J Immunol. 2004 Dec 1;173(11):7017-24 [15557199.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):99-104 [15615857.001]
  • [Cites] Annu Rev Immunol. 2005;23:447-85 [15771578.001]
  • [Cites] Immunity. 2005 Aug;23(2):115-26 [16111631.001]
  • [Cites] Immunity. 2005 Oct;23(4):344-6 [16226499.001]
  • [Cites] Immunity. 2005 Oct;23(4):361-74 [16226502.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1645-54 [16424194.001]
  • [Cites] BMC Bioinformatics. 2006;7:151 [16545118.001]
  • [Cites] Immunol Rev. 2006 Aug;212:8-27 [16903903.001]
  • [Cites] Am J Pathol. 2006 Dec;169(6):2137-47 [17148676.001]
  • [Cites] Cell Mol Biol Lett. 2007;12(1):82-102 [17103092.001]
  • [Cites] Nat Rev Immunol. 2007 Oct;7(10):817-23 [17767193.001]
  • [Cites] J Exp Med. 2004 Oct 18;200(8):1051-62 [15492127.001]
  • [Cites] J Immunol. 1983 Aug;131(2):826-32 [6408190.001]
  • [Cites] J Immunol. 1985 Mar;134(3):1609-18 [2578513.001]
  • [Cites] J Clin Invest. 1991 Feb;87(2):739-42 [1899431.001]
  • [Cites] Adv Immunol. 2007;96:41-101 [17981204.001]
  • [Cites] Int Immunol. 2008 Sep;20(9):1231-7 [18644830.001]
  • [Cites] J Autoimmun. 1991 Apr;4(2):237-48 [1909135.001]
  • [Cites] J Immunol. 2000 Jan 1;164(1):183-90 [10605010.001]
  • [Cites] Cytokine. 2000 Mar;12(3):220-8 [10704248.001]
  • [Cites] J Immunol. 2000 Apr 1;164(7):3919-23 [10725755.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12204-9 [11035773.001]
  • [Cites] Diabetes. 2000 Dec;49(12):2007-11 [11118001.001]
  • [Cites] J Cell Biochem Suppl. 2001;Suppl 37:120-5 [11842437.001]
  • [Cites] J Immunol. 2002 Jun 15;168(12):6159-64 [12055228.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2253-63 [12193690.001]
  • [Cites] J Biol Chem. 2002 Nov 8;277(45):42821-9 [12215441.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Dec;27(6):678-87 [12444027.001]
  • [Cites] Nat Rev Immunol. 2003 Jan;3(1):23-35 [12511873.001]
  • [Cites] J Leukoc Biol. 2003 Feb;73(2):209-12 [12554797.001]
  • [Cites] J Immunol. 2003 Jun 1;170(11):5491-501 [12759426.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3483-6 [12824349.001]
  • [Cites] J Exp Med. 2003 Jul 7;198(1):153-60 [12835483.001]
  • [Cites] J Immunol. 2003 Aug 15;171(4):1652-5 [12902462.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):46138-45 [12963718.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D258-61 [14681407.001]
  • [Cites] J Immunol. 2004 Jan 1;172(1):34-9 [14688306.001]
  • [Cites] Eur J Immunol. 2004 Feb;34(2):447-54 [14768049.001]
  • [Cites] Immunity. 2004 May;20(5):623-35 [15142530.001]
  • [Cites] Science. 2004 Jun 11;304(5677):1678-82 [15192232.001]
  • [Cites] Diabetes. 2004 Sep;53(9):2310-21 [15331540.001]
  • [Cites] Int Immunol. 2004 Oct;16(10):1391-401 [15351783.001]
  • [Cites] Cell. 1993 Sep 24;74(6):1089-100 [8402882.001]
  • (PMID = 18981116.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK079798-01A2; United States / NIDDK NIH HHS / DK / DK058177; United States / NIDDK NIH HHS / DK / R01 DK058177; United States / NCI NIH HHS / CA / P30 CA91842; United States / NIDDK NIH HHS / DK / K08 DK066062; United States / NIDDK NIH HHS / DK / R01 DK079798; United States / NIDDK NIH HHS / DK / P60 DK020579-31; United States / NIDDK NIH HHS / DK / DK020579-31; United States / NIDDK NIH HHS / DK / 5 P60 DK20579; United States / NCI NIH HHS / CA / P30 CA091842; United States / NIDDK NIH HHS / DK / R01 DK079798-01A2; United States / NIDDK NIH HHS / DK / K08 DK066062-05; United States / NIDDK NIH HHS / DK / P60 DK020579; United States / NIDDK NIH HHS / DK / DK058177-09; United States / NIDDK NIH HHS / DK / R01 DK058177-09; United States / NIDDK NIH HHS / DK / DK066062-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS71163; NLM/ PMC2653256
  •  go-up   go-down


87. Mitchell PB, Johnston AK, Corry J, Ball JR, Malhi GS: Characteristics of bipolar disorder in an Australian specialist outpatient clinic: comparison across large datasets. Aust N Z J Psychiatry; 2009 Feb;43(2):109-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper reports on findings from the Black Dog Institute Bipolar Disorders Clinic (BDI-BDC) and compares this dataset with the predominantly outpatient Stanley Foundation Bipolar Disorders Network (SFBN) and Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) samples.
  • METHODS: A total of 217 patients with DSM-IV bipolar disorder were assessed in detail in the BDI-BDC using a series of standardized and non-standardized structured interviews.
  • The SFBN subjects reported higher numbers of overall episodes, but psychotic features and suicide attempts were less common than in the BDI-BDC sample.

  • Genetic Alliance. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19153918.001).
  • [ISSN] 1440-1614
  • [Journal-full-title] The Australian and New Zealand journal of psychiatry
  • [ISO-abbreviation] Aust N Z J Psychiatry
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


88. Davies RP, Less RJ, Lickiss PD, White AJ: Framework materials assembled from magnesium carboxylate building units. Dalton Trans; 2007 Jun 28;(24):2528-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four coordination polymers containing magnesium metal nodes and di- or tricarboxylic acid organic connectors have been synthesised and structurally characterised with the aid of single crystal X-ray diffraction.
  • Mg3(bdc)3(DMA)4 (1) and Mg3(bdc)3(EtOH)2 (2) were prepared from the 1 : 1 reaction of 1,4-benzenedicarboxylic acid (H(2)bdc) with Mg(NO3)2.6H2O in dimethylacetamide (DMA) or EtOH respectively.
  • These tri-magnesium nodes are joined by the bdc ligands in 1 to give a 2D layered structure with coordinated DMA solvent molecules between the layers, whereas in 2 they stack end-on to form a novel 3D network containing 1D Mg carboxylate chains.
  • Both 1 and 2 are moderately hygroscopic, and powder X-ray diffraction and thermogravimetric analysis studies show them to be interconvertible with Mg(bdc) and the hydrated complex Mg(bdc)(H2O)2 via a series of solid-state reactions.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17563788.001).
  • [ISSN] 1477-9226
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


89. Chu WH, Zhu W: Isolation of Bdellovibrio as biological therapeutic agents used for the treatment of Aeromonas hydrophila infection in fish. Zoonoses Public Health; 2010 Jun;57(4):258-64

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The optimum temperature for the growth of BdC-1 was between 15-37 degrees C and with optimal activity at temperatures of 25-30 degrees C.
  • The ability of BdC-1 to lyse A. hydrophila was similar in the pH range of 6.5 to 8.5.
  • Immersion of fish in water containing different concentrations of BdC-1 was used in protection against an experimental infection of A. hydrophila J-1.
  • Results show that the mortality of groups immersed with BdC-1 was lower than the group without BdC-1.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19486499.001).
  • [ISSN] 1863-2378
  • [Journal-full-title] Zoonoses and public health
  • [ISO-abbreviation] Zoonoses Public Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


90. Felger JC, Abe T, Kaunzner UW, Gottfried-Blackmore A, Gal-Toth J, McEwen BS, Iadecola C, Bulloch K: Brain dendritic cells in ischemic stroke: time course, activation state, and origin. Brain Behav Immun; 2010 Jul;24(5):724-37
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One cell type involved in both innate and adaptive immunity is the dendritic cell (DC).
  • A DC population residing in the healthy brain (bDC) was identified using a transgenic mouse expressing enhanced yellow fluorescent protein (EYFP) under the promoter for the DC marker, CD11c (CD11c/EYFP Tg).
  • To determine if bDC are involved in the immune response to cerebral ischemia, transient (40 min) middle cerebral artery occlusion (MCAO) followed by 6, 24, or 72 h reperfusion was conducted in CD11c/EYFP Tg mice.
  • To distinguish resident bDC from the infiltrating peripheral DC, radiation chimeras [1. wild type (WT) hosts restored with CD11c/EYFP Tg bone marrow (BM) or 2.
  • These data confirmed that DC populating the core of the infarct at 72 h were of peripheral origin, whereas those in the border region were comprised primarily of resident bDC.
  • Compared to microglia, bDC displayed increased major histocompatibility class II (MHC II) and co-stimulatory molecules following MCAO-reperfusion.
  • High levels of MHC II and the co-stimulatory molecule CD80 on bDC at 72 h corresponded to peak lymphocyte infiltration, and suggested a functional interaction between these two immune cell populations.

  • MedlinePlus Health Information. consumer health - Ischemic Stroke.
  • MedlinePlus Health Information. consumer health - Stroke.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • [Cites] Trends Immunol. 2003 Jun;24(6):314-9 [12810107.001]
  • [Cites] Eur J Immunol. 2002 Oct;32(10):2888-96 [12355442.001]
  • [Cites] Stroke. 2003 Jul;34(7):1790-5 [12805500.001]
  • [Cites] J Neurosci. 2003 Aug 27;23(21):7922-30 [12944523.001]
  • [Cites] J Exp Med. 2003 Sep 1;198(5):725-36 [12939340.001]
  • [Cites] J Immunol. 2003 Dec 15;171(12):6549-55 [14662856.001]
  • [Cites] J Immunol. 2004 Mar 1;172(5):2778-84 [14978077.001]
  • [Cites] Stroke. 1994 Apr;25(4):869-75; discussion 875-6 [8160235.001]
  • [Cites] J Cereb Blood Flow Metab. 1994 Jul;14(4):697-8 [7516936.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):241-8 [8546211.001]
  • [Cites] Blood. 1997 Aug 1;90(3):986-93 [9242527.001]
  • [Cites] Adv Exp Med Biol. 1997;417:55-7 [9286337.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10873-8 [9380727.001]
  • [Cites] Nat Immunol. 2004 Dec;5(12):1243-50 [15543150.001]
  • [Cites] J Neurosci. 2005 Mar 9;25(10):2504-12 [15758158.001]
  • [Cites] Hepatology. 2006 Jan;43(1):154-62 [16374849.001]
  • [Cites] Nat Med. 2006 Feb;12(2):225-9 [16432513.001]
  • [Cites] J Cereb Blood Flow Metab. 2006 May;26(5):654-65 [16121126.001]
  • [Cites] Circulation. 2006 May 2;113(17):2105-12 [16636173.001]
  • [Cites] J Immunol. 2006 Jun 1;176(11):6523-31 [16709809.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11784-9 [16864778.001]
  • [Cites] Stroke. 2007 Feb;38(2 Suppl):783-8 [17261738.001]
  • [Cites] J Neuroimmunol. 2007 Mar;184(1-2):53-68 [17188755.001]
  • [Cites] Mol Cell Neurosci. 2007 Jul;35(3):490-500 [17560122.001]
  • [Cites] J Neurosci. 2007 Jul 4;27(27):7083-93 [17611261.001]
  • [Cites] Neurosci Lett. 2007 Sep 25;425(2):110-3 [17868996.001]
  • [Cites] Nature. 2007 Sep 27;449(7161):419-26 [17898760.001]
  • [Cites] J Neurosci. 2008 Feb 13;28(7):1649-58 [18272685.001]
  • [Cites] J Comp Neurol. 2008 Jun 10;508(5):687-710 [18386786.001]
  • [Cites] Neuropharmacology. 2008 Sep;55(3):310-8 [18308346.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17913-8 [18997009.001]
  • [Cites] Nat Med. 2009 Feb;15(2):192-9 [19169263.001]
  • [Cites] Nat Med. 2009 Feb;15(2):138-9 [19197285.001]
  • [Cites] Neuroscience. 2009 Feb 6;158(3):1098-111 [18597949.001]
  • [Cites] Neuroscience. 2009 Feb 6;158(3):1049-61 [18789376.001]
  • [Cites] J Neurosci. 2009 Feb 18;29(7):2089-102 [19228962.001]
  • [Cites] Stroke. 2009 May;40(5):1849-57 [19265055.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2717-26 [11160337.001]
  • [Cites] J Neuroimmunol. 2001 May 1;116(1):5-14 [11311324.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 22;98(11):6295-300 [11371643.001]
  • [Cites] Stroke. 2001 May;32(5):1208-15 [11340235.001]
  • [Cites] Nat Med. 2001 Dec;7(12):1356-61 [11726978.001]
  • [Cites] Nat Biotechnol. 2002 Jan;20(1):87-90 [11753368.001]
  • [Cites] Brain Res. 2002 Apr 5;932(1-2):110-9 [11911867.001]
  • [Cites] Stroke. 2002 Apr;33(4):1129-34 [11935071.001]
  • [Cites] J Neuroimmunol. 2002 Aug;129(1-2):125-32 [12161028.001]
  • [Cites] Stroke. 2003 Jul;34(7):1704-9 [12805489.001]
  • (PMID = 19914372.001).
  • [ISSN] 1090-2139
  • [Journal-full-title] Brain, behavior, and immunity
  • [ISO-abbreviation] Brain Behav. Immun.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / AG016765-100001; United States / NINDS NIH HHS / NS / R01 NS034179; United States / NIA NIH HHS / AG / P01 AG016765-100001; United States / NINDS NIH HHS / NS / R01 NS035806; United States / NINDS NIH HHS / NS / NS35806; United States / NINDS NIH HHS / NS / R37 NS034179; United States / NIA NIH HHS / AG / P01 AG016765; United States / NINDS NIH HHS / NS / NS34179
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD11c
  • [Other-IDs] NLM/ NIHMS165073; NLM/ PMC2885548
  •  go-up   go-down


91. Osunkoya AO, Young AN, Wang W, Netto GJ, Epstein JI: Comparison of gene expression profiles in tubulocystic carcinoma and collecting duct carcinoma of the kidney. Am J Surg Pathol; 2009 Jul;33(7):1103-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of gene expression profiles in tubulocystic carcinoma and collecting duct carcinoma of the kidney.
  • The relationship between tubulocystic carcinoma and collecting duct carcinoma of the kidney remains controversial.
  • Some experts are of the opinion that the tumors are related, considering tubulocystic carcinoma to be synonymous with low-grade collecting duct carcinoma.
  • However, others maintain that the 2 are distinct, unrelated entities on the basis of morphologic features and clinical outcome.
  • To explore the relationship between tubulocystic carcinoma and collecting duct carcinoma, we compared the expression of several gene products at the mRNA level in cohorts of each tumor subtype.
  • Seven cases of tubulocystic carcinoma and 8 cases of collecting duct carcinoma were identified.
  • Tubulocystic carcinoma was characterized by relative overexpression of vimentin, p53, and alpha methylacyl CoA racemase, compared with collecting duct carcinoma (P<0.05 for each gene, t test).
  • In general, tubulocystic carcinoma expressed higher levels of E-cadherin and CD10, whereas collecting duct carcinoma expressed higher levels of cytokeratin 19; however, these trends did not reach statistical significance in this study cohort.
  • Tubulocystic carcinoma and collecting duct carcinoma did not express cytokeratin 7 differentially.
  • Our study demonstrates that tubulocystic carcinoma and collecting duct carcinoma have different expression profiles of selected genes, including vimentin, p53, and alpha methylacyl CoA racemase.
  • Overall, these findings support the view that tubulocystic carcinoma and collecting duct carcinoma should be considered as 2 distinct entities at the molecular level.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Renal Cell / genetics. Kidney Neoplasms / genetics. Kidney Tubules / pathology

  • Genetic Alliance. consumer health - Collecting Duct Carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19390420.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


92. Sibony M, Vieillefond A: [Non clear cell renal cell carcinoma. 2008 update in renal tumor pathology]. Ann Pathol; 2008 Oct;28(5):381-401
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non clear cell renal cell carcinoma. 2008 update in renal tumor pathology].
  • [Transliterated title] Les tumeurs du rein qui ne sont pas des carcinomes à cellules claires. Etat des lieux en 2008.
  • Non clear cell renal cell carcinomas represent almost 20% of all renal neoplasms.
  • Since molecular techniques are expensive, diagnosis still relies on morphological and immuno-histochemical criteria detailed hereby.
  • Papillary renal cell carcinomas are the most important group and its classification is more and more complex.
  • It encompasses low-grade papillary carcinomas (type 1 papillary renal cell carcinoma, oncocytic papillary renal cell carcinoma) and high-grade papillary carcinomas (type 2 papillary renal cell carcinoma, juvenile papillary carcinoma corresponding to renal carcinoma associated with Xp11.2 translocations and unclassified carcinomas).
  • Mucinous tubular and spindle cell carcinoma and tubulocystic carcinoma are new entities, actually considered by some authors as low-grade papillary carcinomas.
  • The so-called carcinoma of collecting ducts of Bellini and renal medullary carcinoma should be considered as intrarenal urothelial carcinoma or as high-grade papillary or unclassified carcinoma.
  • Sarcomatoid carcinoma derives from morphological progression of any type of renal cell carcinoma.
  • The group of oncocytomas/chromophobe renal cell carcinomas can be considered as a spectrum from benign (oncocytoma) to malignant neoplasm (chromophobe renal cell carcinoma).
  • Renal epithelial and stromal tumors (REST) is a new concept gathering two benign mixed mesenchymal and epithelial tumors: cystic nephroma and mixed epithelial and stromal tumors (MEST).
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adenoma, Oxyphilic / classification. Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / pathology. Carcinoma / classification. Carcinoma / genetics. Carcinoma / pathology. Chromosome Mapping. Chromosomes, Human. Humans. Immunohistochemistry. Kidney / pathology. Kidney Tubules, Collecting / pathology. Necrosis

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068393.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 84
  •  go-up   go-down


93. Wang GM, Xue SY, Li H, Liu HL: Poly[bis(mu4-benzene-1,2-dicarboxylato)di-mu3-isonicotinato-dilanthanum(III)]. Acta Crystallogr C; 2009 Dec;65(Pt 12):m469-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poly[bis(mu4-benzene-1,2-dicarboxylato)di-mu3-isonicotinato-dilanthanum(III)].
  • The La centres are linked by the carboxylate groups of isonicotinate (IN(-)) and benzene-1,2-dicarboxylate (BDC(2-)) ligands to form La-carboxylate chains, which are further expanded into a three-dimensional framework with nanometre-sized channels by La-N bonds.
  • In the construction of the resultant architecture, in tricapped trigonal prismatic coordination geometries by eight carboxylate O atoms and one pyridyl N atom, while the BDC ligands link to four different cations each, displaying penta- and heptadentate chelating-bridging modes, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19966429.001).
  • [ISSN] 1600-5759
  • [Journal-full-title] Acta crystallographica. Section C, Crystal structure communications
  • [ISO-abbreviation] Acta Crystallogr C
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


94. Doonan CJ, Morris W, Furukawa H, Yaghi OM: Isoreticular metalation of metal-organic frameworks. J Am Chem Soc; 2009 Jul 15;131(27):9492-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sequential covalent transformation and metalation were performed on (Zn(4)O)(3)(BDC-NH(2))(3)(BTB)(4) with maintenance of crystallinity and porosity.
  • Reaction of (Zn(4)O)(3)(BDC-NH(2))(3)(BTB)(4) with 2-pyridinecarboxaldehyde in toluene at room temperature for 5 days resulted in the formation of the extended crystalline structure (Zn(4)O)(3)(BDC-C(6)H(5)N(2))(3)(BTB)(4), which possesses iminopyridine moieties covalently bound to the organic links of the framework.
  • Subsequent reaction with PdCl(2)(CH(3)CN)(2) in CH(2)Cl(2) at room temperature for 12 h yielded the metalated metal-organic framework (Zn(4)O)(3)(BDC-C(6)H(5)N(2)PdCl(2))(3)(BTB)(4).
  • Both functionalized materials retained high crystallinity and were permanently porous with high surface areas [3200 and 1700 m(2) g(-1) for (Zn(4)O)(3)(BDC-C(6)H(5)N(2))(3)(BTB)(4) and (Zn(4)O)(3)(BDC-C(6)H(5)N(2)PdCl(2))(3)(BTB)(4), respectively.].

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19534523.001).
  • [ISSN] 1520-5126
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Zhang J, Wojtas L, Larsen RW, Eddaoudi M, Zaworotko MJ: Temperature and concentration control over interpenetration in a metal-organic material. J Am Chem Soc; 2009 Dec 2;131(47):17040-1
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A pillared framework formed from 4,4'-bipyridine (bipy) and sheets of dinuclear Cd(2) nodes and 1,4-benzenedicarboxylic acid (bdc) linkers can be prepared in both interpenetrated and noninterpenetrated forms by simply varying the temperature or concentration of the reaction.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19891485.001).
  • [ISSN] 1520-5126
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Larsen RW, McManus GJ, Perry JJ 4th, Rivera-Otero E, Zaworotko MJ: Spectroscopic characterization of hydroxylated nanoballs in methanol. Inorg Chem; 2007 Jul 23;46(15):5904-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this report, the photophysical properties of self-assembled [Cu(2)(5-OH-bdc)(2)L(2)](12) [where (5-OH-bdc)(2-) = 5-hydroxybenzene-1,3-dicarboxylate and L is a dimethyl sulfoxide, methanol, or water ligand] hydroxylated nanoballs (OH-nanoball) were examined in methanol using optical absorption and steady-state and time-resolved fluorescence methods.
  • The emission from the OH-nanoball is significantly quenched relative to the free ligand [Phi(5-OH-H(2)bdc) = 0.014 and Phi(OH-nanoball) = (5.6 +/- 0.5) x 10-5].
  • The addition of bases such as imidazole results in an increase in the emission intensity of the OH-nanoball solution, indicating dissociation of the [Cu(2)(5-OH-bdc)(2)L(2)](12) units.
  • Although the mechanism of (5-OH-bdc)(2-) quenching within the OH-nanoball is not clear, it is likely due to interactions between the ligand pi system and the Cu d orbitals.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROGEN .
  • Hazardous Substances Data Bank. METHANOL .
  • Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .
  • Hazardous Substances Data Bank. Water .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17585758.001).
  • [ISSN] 0020-1669
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ligands; 059QF0KO0R / Water; 7YNJ3PO35Z / Hydrogen; Y4S76JWI15 / Methanol; YOW8V9698H / Dimethyl Sulfoxide
  •  go-up   go-down


97. Yang XP, Jones RA, Wong WK, Lynch V, Oye MM, Holmes AL: Design and synthesis of a near infra-red luminescent hexanuclear Zn-Nd prism. Chem Commun (Camb); 2006 May 7;(17):1836-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Design and synthesis of a near infra-red luminescent hexanuclear Zn-Nd prism.
  • The use of the Schiff-base ligand N,N'-bis(5-bromo-3-methoxysalicylidene)propylene-1,3-diamine (H2L) and 1,4-benzenedicarboxylate (BDC) enables the construction of the hexanuclear luminescent Zn-Nd complex [Zn4Nd2L4(1,4-BDC)2].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16622500.001).
  • [ISSN] 1359-7345
  • [Journal-full-title] Chemical communications (Cambridge, England)
  • [ISO-abbreviation] Chem. Commun. (Camb.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


98. Elwatidy S: Bifrontal decompressive craniectomy is a life-saving procedure for patients with nontraumatic refractory brain edema. Br J Neurosurg; 2009 Feb;23(1):56-62
Genetic Alliance. consumer health - Edema.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bifrontal decompressive craniectomy (BDC) is performed as last resort treatment for patients with posttraumatic RBE.
  • In this series the author treated 5 adult patients with non traumatic RBE using BDC.
  • BDC is an effective method of surgical decompression in patients with RBE; the procedure should be performed quickly after clinical deterioration to prevent irreversible secondary brain damage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19234910.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


99. Aquino A, Wanderley KA, Paiva-Santos Cde O, de Sá GF, Alexandre Mda R, Júnior SA, Navickiene S: Coordination polymer adsorbent for matrix solid-phase dispersion extraction of pesticides during analysis of dehydrated Hyptis pectinata medicinal plant by GC/MS. Talanta; 2010 Dec 15;83(2):631-6
Hazardous Substances Data Bank. AMETRYNE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The coordination polymer [Zn(BDC)(H(2)O)(2)](n) was tested for extraction of pyrimethanil, ametryn, dichlofluanid, tetraconazole, flumetralin, kresoxim-methyl and tebuconazole from the medicinal plant Hyptis pectinata, with analysis using gas chromatography-mass spectrometry in selected ion monitoring mode (GC/MS, SIM).
  • Experiments carried out at different fortification levels (0.1, 0.5 and 1.0 μg g(-1)) resulted in recoveries in the range 73-97%, and RSD values were between 5 and 12% for the [Zn(BDC)(H(2)O)(2)](n) sorbent.
  • Comparison between [Zn(BDC)(H(2)O)(2)](n) and the commercial phase C(18)-bonded silica showed good performance of the [Zn(BDC)(H(2)O)(2)](n) polymeric sorbent for the pesticides tested.

  • MedlinePlus Health Information. consumer health - Pesticides.
  • Hazardous Substances Data Bank. TEBUCONAZOLE .
  • Hazardous Substances Data Bank. DICHLOFLUANID .
  • Hazardous Substances Data Bank. PYRIMETHANIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • (PMID = 21111184.001).
  • [ISSN] 1873-3573
  • [Journal-full-title] Talanta
  • [ISO-abbreviation] Talanta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aniline Compounds; 0 / Chlorobenzenes; 0 / Methacrylates; 0 / Pesticides; 0 / Phenylacetates; 0 / Plant Extracts; 0 / Polymers; 0 / Pyrimidines; 0 / Triazines; 0 / Triazoles; 0 / tetraconazole; 0LXZ062TTB / kresoxim-methyl; 107534-96-3 / tebuconazole; 6IA5HP6C8Z / pyrimethanil; 76A92XU36Y / dichlofluanid; 834-12-8 / ametryne
  •  go-up   go-down


100. Atamna H, Newberry J, Erlitzki R, Schultz CS, Ames BN: Biotin deficiency inhibits heme synthesis and impairs mitochondria in human lung fibroblasts. J Nutr; 2007 Jan;137(1):25-30
Hazardous Substances Data Bank. BIOTIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four of the 5 biotin-dependent carboxylases (BDC) are in the mitochondria.
  • BDC replace intermediates in the Krebs [tricarboxylic acid (TCA)] cycle that are regularly removed for the synthesis of key metabolites such as heme or amino acids.
  • Biotin-deficient primary human lung fibroblasts (IMR90) lost their BDC and senesced before biotin-sufficient cells.

  • COS Scholar Universe. author profiles.
  • Coriell Cell Repositories. culture/stock collections - Coriell Cell Repositories .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17182796.001).
  • [ISSN] 0022-3166
  • [Journal-full-title] The Journal of nutrition
  • [ISO-abbreviation] J. Nutr.
  • [Language] eng
  • [Grant] United States / NCCIH NIH HHS / AT / K05 AT001323; United States / NIMHD NIH HHS / MD / P60 MD00222
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oxidants; 42VZT0U6YR / Heme; 6SO6U10H04 / Biotin
  •  go-up   go-down






Advertisement